



(51) International Patent Classification:

A61P 25/14 (2006.01) A61K 31/506 (2006.01)

(21) International Application Number:

PCT/JP2020/017652

(22) International Filing Date:

24 April 2020 (24.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

16/395,531 26 April 2019 (26.04.2019) US

(71) Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD. [JP/JP]; 6-8, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka, 5418524 (JP).

(72) Inventors: KURITA Mitsumasa; c/o SUMITOMO DAINIPPON PHARMA CO., LTD., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, 5540022 (JP). IKEDA Yuki; c/o SUMITOMO DAINIPPON PHARMA CO., LTD., 33-94, Enoki-cho, Suita-shi, Osaka, 5640053 (JP). NAKATO Mitsuhiro; c/o SUMITOMO DAINIPPON PHARMA CO., LTD., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, 5540022 (JP).

(74) Agent: YAMAMOTO Shusaku et al.; GRAND FRONT OSAKA TOWER C, 3-1, Ofuka-cho, Kita-ku, Osaka-shi, Osaka, 5300011 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

(54) Title: THERAPEUTIC DRUG FOR DYSKINESIA

[Fig. 2]

FIG.2



(57) Abstract: The present invention provides a therapeutic drug that is useful for levodopa induced dyskinesia in Parkinson's disease. In particular, the present invention provides a composition and method for treating, improving, suppressing the progression, or preventing motor complications associated with levodopa therapy for Parkinson's disease, especially levodopa induced dyskinesia (PD-LID), comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.



Description

Title of Invention: THERAPEUTIC DRUG FOR DYSKINESIA

Technical Field

[0001] The present invention relates to a formulation for treating levodopa induced dyskinesia in Parkinson's disease by parenteral administration (e.g., transdermal administration), comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof that is useful as a medicament as an active ingredient.

Background Art

[0002] Parkinson's disease is a progressive neurodegenerative disease with a primary symptom of extrapyramidal function abnormality. Pathologically, loss of dopaminergic neurons and alpha-synuclein deposition in the substantia nigra pars compacta are observed. Clinically, various motor symptoms such as akinesia, tremor, rigidity, and loss of postural reflexes are exhibited.

[0003] Parkinson's disease therapy is fundamentally a drug therapy intended to supplement intracerebral dopamine. A drug comprising levodopa (L-dopa), which is a dopamine precursor, is used as the first-line drug for the initial therapy of Parkinson's disease. However, motor complications such as Parkinson's Disease Levodopa induced dyskinesia (hereinafter, also referred to as "PD-LID") are manifested in almost all patients undergoing levodopa therapy with the progression in pathological conditions.

[0004] The frequency of developing PD-LID in 5 years after the initial levodopa therapy is 30 to 50%. The frequency increases with the progression of the pathological condition and reaches 50 to 100% in 10 years after the initial therapy. Peak-dose dyskinesia is known as an exemplary symptom of PD-LID, which is an involuntary movement manifested in the face, tongue, neck, limbs, body trunk, or the like when the blood levodopa concentration is high.

[0005] Patent Literature 1 [Japanese Laid-Open Publication No. 11-228414] has a disclosure on transdermally absorbed tandospirone agents.

Citation List

Patent Literature

[0006] PTL 1: Japanese Laid-Open Publication No. 11-228414

[0007]

Summary of Invention

Solution to Problem

[0008] As a result of diligent studies, the inventors have discovered that a useful technology for treatment, improvement, suppression of progression, or prevention with a high effect of improving of Parkinson's disease levodopa induced dyskinesia (PD-LID) or

the like can be provided, as compared to oral administration, by parenterally administering (e.g., transdermal administration, intradermal administration, subcutaneous administration, intramuscular administration, or the like) tandospirone or a pharmaceutically acceptable salt or prodrug thereof. The present invention provides transdermally administered pharmaceutical compositions for improving PD-LID, comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, and methods of treating, improving, suppressing the progression, and preventing motor complications of Parkinson's disease by parenteral administration including tandospirone or a pharmaceutically acceptable salt or prodrug thereof.

[0009] Specifically, the present invention comprises the following.

[0010] (Item 1)

A composition for treating, improving, suppressing the progression, or preventing motor complications associated with levodopa therapy for Parkinson's disease, comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 2)

The composition of any one of the preceding items, wherein the parenteral administration is selected from transdermal administration, intradermal administration, subcutaneous administration, intramuscular administration, and a combination thereof.

(Item 3)

The composition of any one of the preceding items, wherein the parenteral administration has sustainability or is sustainably administered.

(Item 4)

The composition of any one of the preceding items, wherein the parenteral administration comprises transdermal administration.

(Item 5)

The composition of any one of the preceding items, wherein the motor complications comprise levodopa induced dyskinesia (PD-LID).

(Item 6)

A composition for treating, improving, or preventing motor complications associated with levodopa therapy for Parkinson's disease, comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein levodopa induced dyskinesia (PD-LID) is improved without resulting in a rebound symptom, and wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is transdermally administered.

(Item 7)

The composition of any one of the preceding items, wherein levodopa induced

dyskinesia (PD-LID) comprises peak-dose dyskinesia, diphasic dyskinesia, and a combination thereof.

(Item 8)

The composition of any one of the preceding items, wherein the treatment, improvement, suppression of progression, or prevention of motor complications comprises improvement, suppression of progression, or prevention of a levodopa induced dyskinesia (PD-LID) symptom, reduction of a period of levodopa induced dyskinesia (PD-LID) manifestation, or a combination thereof.

(Item 9)

A composition for accomplishing improvement, suppression of progression, or prevention of a levodopa induced dyskinesia (PD-LID) symptom, reduction of a period of levodopa induced dyskinesia (PD-LID) manifestation, or a combination thereof, comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 10)

The composition of any one of the preceding items, wherein the improvement of a levodopa induced dyskinesia (PD-LID) symptom is a clinically significant improvement or greater.

(Item 11)

The composition of any one of the preceding items, wherein the improvement a levodopa induced dyskinesia (PD-LID) symptom is to a sufficient level to attain a clinical effect.

(Item 12)

The composition of any one of the preceding items, wherein the composition is a transdermally administered formulation.

(Item 13)

The composition of any one of the preceding items, wherein the composition is an adhesive formulation.

(Item 14)

The composition of any one of the preceding items, wherein a transdermally administered formulation is a tape/patch.

(Item 15)

The composition of any one of the preceding items, wherein a drug dosage of the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is 0.1 to 100 mg per day as a free form of tandospirone.

(Item 16)

The composition of any one of the preceding items, wherein an amount of drug pen-

etration for the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is 0.1 to 20 mg per day as a free form of tandospirone.

(Item 17)

The composition of any one of the preceding items, wherein the composition is a transdermally administered formulation, and a total applied area per dose is 1 to 100 cm².

(Item 18)

The composition of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered so that a human blood (plasma) tandospirone concentration is 0.05 to 20 ng/mL for 12 hours or longer per day.

(Item 19)

The composition of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered so that a human blood (plasma) tandospirone concentration is 0.05 to 20 ng/mL for 8 to 16 hours after administration of the tandospirone or a pharmaceutically acceptable salt or prodrug thereof.

(Item 20)

The composition of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is an adjunct of levodopa.

(Item 21)

The composition of any one of the preceding items, which is used with levodopa as the fixed-dose combination or concomitantly as separate formulations.

(Item 22)

A medicament for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID, comprising a combination of tandospirone or a pharmaceutically acceptable salt or prodrug thereof and (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 23)

A medicament for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID, comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered in combination with (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 24)

A medicament for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID, comprising (1) levodopa or (2) levodopa and a metabolizing

enzyme inhibitor of levodopa, wherein the (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa is administered in combination with tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 25)

A composition for improving the exacerbation in quality of response to levodopa therapy of a Parkinson's disease patient with dyskinesia, comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 26)

The medicament or composition of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is a free form of tandospirone.

(Item 1A)

A method for treating, improving, or preventing motor complications associated with levodopa therapy for Parkinson's disease, comprising parenterally administering an effective amount of tandospirone or a pharmaceutically acceptable salt or prodrug thereof to a subject.

(Item 2A)

The method of any one of the preceding items, wherein the parenteral administration is selected from transdermal administration, intradermal administration, subcutaneous administration, intramuscular administration, and a combination thereof.

(Item 3A)

The method of any one of the preceding items, wherein the parenteral administration has sustainability or is sustainably administered.

(Item 4A)

The method of any one of the preceding items, wherein the parenteral administration comprises transdermal administration.

(Item 5A)

The method of any one of the preceding items, wherein the motor complications comprise levodopa induced dyskinesia (PD-LID).

(Item 6A)

A method of treating, improving, or preventing motor complications associated with levodopa therapy for Parkinson's disease, comprising transdermally administering an effective amount of tandospirone or a pharmaceutically acceptable salt or prodrug thereof to a subject, such that levodopa induced dyskinesia (PD-LID) is improved without a rebound symptom.

(Item 7A)

The method of any one of the preceding items, wherein levodopa induced dyskinesia (PD-LID) comprises peak-dose dyskinesia, diphasic dyskinesia, and a combination thereof.

(Item 8A)

The method of any one of the preceding items, wherein the treatment, improvement, suppression of progression, or prevention of motor complications comprises improvement, suppression of progression, or prevention of a levodopa induced dyskinesia (PD-LID) symptom, reduction of a period of levodopa induced dyskinesia (PD-LID) manifestation, or a combination thereof.

(Item 9A)

A method for accomplishing improvement, suppression of progression, or prevention of a levodopa induced dyskinesia (PD-LID) symptom, reduction of a period of levodopa induced dyskinesia (PD-LID) manifestation, or a combination thereof, comprising parenterally administering an effective amount of tandospirone or a pharmaceutically acceptable salt or prodrug thereof to a subject.

(Item 10A)

The method of any one of the preceding items, wherein the improvement of a levodopa induced dyskinesia (PD-LID) symptom is a clinically significant improvement or greater.

(Item 11A)

The method of any one of the preceding items, wherein the improvement of a levodopa induced dyskinesia (PD-LID) symptom is to a sufficient level to attain a clinical effect.

(Item 12A)

The method of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is provided as a transdermally administered formulation.

(Item 13A)

The method of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is provided as an adhesive formulation.

(Item 14A)

The method of any one of the preceding items, wherein the transdermally administered formulation is a tape/patch.

(Item 15A)

The method of any one of the preceding items, wherein a drug dosage of the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is 0.1 to 100 mg per day as a free form of tandospirone.

(Item 16A)

The method of any one of the preceding items, wherein an amount of drug penetration for the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is 0.1 to 20 mg per day as a free form of tandospirone.

(Item 17A)

The method of any one of the preceding items, wherein the administration is accomplished with a transdermally administered formulation, and a total applied area per dose is 1 to 100 cm².

(Item 18A)

The method of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered so that a human blood (plasma) tandospirone concentration is 0.05 to 20 ng/mL for 12 hours or longer per day.

(Item 19A)

The method of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered so that a human blood (plasma) tandospirone concentration is 0.05 to 20 ng/mL for 8 to 16 hours after administration of the tandospirone or a pharmaceutically acceptable salt or prodrug thereof.

(Item 20A)

The method of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is an adjunct of levodopa.

(Item 21A)

The method of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is used with levodopa as the fixed-dose combination or concomitantly as separate formulations.

(Item 22A)

A method for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID in a subject, comprising administering to the subject an effective amount of a combination of an effective amount of tandospirone or a pharmaceutically acceptable salt or prodrug thereof and (1) an effective amount of levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa, wherein the effective amount of tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 23A)

The method of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof and the (1) or (2) are administered simultaneously or at different times.

(Item 24A)

A composition for improving the exacerbation in quality of response to levodopa

therapy of a Parkinson's disease patient with dyskinesia, comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein an effective amount of the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 25A)

The method of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt thereof is a free form of tandospirone.

(Item 1B)

Use of tandospirone or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for treating, improving, or preventing motor complications associated with levodopa therapy for Parkinson's disease, wherein the medicament is parenterally administered.

(Item 2B)

The use of any one of the preceding items, wherein the parenteral administration is selected from transdermal administration, intradermal administration, subcutaneous administration, intramuscular administration, and a combination thereof.

(Item 3B)

The use of any one of the preceding items, wherein the parenteral administration has sustainability or is sustainably administered.

(Item 4B)

The use of any one of the preceding items, wherein the parenteral administration comprises transdermal administration.

(Item 5B)

The use of any one of the preceding items, wherein the motor complications comprise levodopa induced dyskinesia (PD-LID).

(Item 6B)

Use in the manufacture of a medicament comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof for the treatment, improvement, or prevention of motor complications associated with levodopa therapy for Parkinson's disease, wherein levodopa induced dyskinesia (PD-LID) is improved without resulting in a rebound symptom, and wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is transdermally administered.

(Item 7B)

The use of any one of the preceding items, wherein levodopa induced dyskinesia (PD-LID) comprises peak-dose dyskinesia, diphasic dyskinesia, and a combination thereof.

(Item 8B)

The use of any one of the preceding items, wherein the treatment, improvement, sup-

pression of progression, or prevention of motor complications comprises improvement, suppression of progression, or prevention of a levodopa induced dyskinesia (PD-LID) symptom, reduction of a period of levodopa induced dyskinesia (PD-LID) manifestation, or a combination thereof.

(Item 9B)

Use in the manufacture of a medicament comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof for accomplishing the improvement, suppression of progression, or prevention of a levodopa induced dyskinesia (PD-LID) symptom, reduction of a period of levodopa induced dyskinesia (PD-LID) manifestation, or a combination thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 10B)

The use of any one of the preceding items, wherein the improvement of a levodopa induced dyskinesia (PD-LID) symptom is a clinically significant improvement or greater.

(Item 11B)

The use of any one of the preceding items, wherein the improvement of a levodopa induced dyskinesia (PD-LID) symptom is to a sufficient level to attain a clinical effect.

(Item 12B)

The use of any one of the preceding items, wherein the medicament is a transdermally administered formulation.

(Item 13B)

The use of any one of the preceding items, wherein the medicament is an adhesive formulation.

(Item 14B)

The use of any one of the preceding items, wherein the transdermally administered formulation is a tape/patch.

(Item 15B)

The use of any one of the preceding items, wherein a drug dosage of the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is 0.1 to 100 mg per day as a free form of tandospirone.

(Item 16B)

The use of any one of the preceding items, wherein an amount of drug penetration for the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is 0.1 to 20 mg per day as a free form of tandospirone.

(Item 17B)

The use of any one of the preceding items, wherein the medicament is a transdermally administered formulation, and a total applied area per dose is 1 to 100 cm².

(Item 18B)

The use of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered so that a human blood (plasma) tandospirone concentration is 0.05 to 20 ng/mL for 12 hours or longer per day.

(Item 19B)

The use of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered so that a human blood (plasma) tandospirone concentration is 0.05 to 20 ng/mL for 8 to 16 hours after administration of the tandospirone or a pharmaceutically acceptable salt or prodrug thereof.

(Item 20B)

The use of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is an adjunct of levodopa.

(Item 21B)

The use of any one of the preceding items, wherein the medicament is used with levodopa as the fixed-dose combination or concomitantly as separate formulations.

(Item 22B)

Use in the manufacture of a medicament for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID, wherein the medicament comprises a combination of tandospirone or a pharmaceutically acceptable salt or prodrug thereof and (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 23B)

Use in the manufacture of a medicament for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID, wherein the medicament comprises tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered in combination with (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 24B)

Use in the manufacture of a medicament for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID, wherein the medicament comprises (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa, wherein the (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa is administered in combination with tandospirone or a pharmaceutically acceptable salt or prodrug thereof, and wherein the tandospirone or a pharmaceutically

acceptable salt or prodrug thereof is parenterally administered.

(Item 25B)

Use in the manufacture of a medicament comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof for improving the exacerbation in quality of response to levodopa therapy of a Parkinson's disease patient with dyskinesia, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 26B)

The use of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt thereof is a free form of tandospirone.

(Item 1C)

Tandospirone or a pharmaceutically acceptable salt or prodrug thereof for treating, improving, or preventing motor complications associated with levodopa therapy for Parkinson's disease, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 2C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, wherein the parenteral administration is selected from transdermal administration, intradermal administration, subcutaneous administration, intramuscular administration, and a combination thereof.

(Item 3C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, wherein the parenteral administration has sustainability or is sustainably administered.

(Item 4C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, wherein the parenteral administration comprises transdermal administration.

(Item 5C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, wherein the motor complications comprise levodopa induced dyskinesia (PD-LID).

(Item 6C)

Tandospirone or a pharmaceutically acceptable salt or prodrug thereof for treating, improving, or preventing motor complications associated with levodopa therapy for Parkinson's disease, wherein levodopa induced dyskinesia (PD-LID) is improved without resulting in a rebound symptom, and wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is transdermally administered.

(Item 7C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, wherein levodopa induced dyskinesia (PD-LID) comprises peak-dose dyskinesia, diphasic dyskinesia, and a combination thereof.

(Item 8C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, wherein the treatment, improvement, suppression of progression, or prevention of motor complications comprises improvement, suppression of progression, or prevention of a levodopa induced dyskinesia (PD-LID) symptom, reduction of a period of levodopa induced dyskinesia (PD-LID) manifestation, or a combination thereof.

(Item 9C)

Tandospirone or a pharmaceutically acceptable salt or prodrug thereof for accomplishing the improvement, suppression of progression, or prevention of a levodopa induced dyskinesia (PD-LID) symptom, reduction of a period of levodopa induced dyskinesia (PD-LID) manifestation, or a combination thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 10C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, wherein the improvement of a levodopa induced dyskinesia (PD-LID) symptom is a clinically significant improvement or greater.

(Item 11C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, wherein the improvement of a levodopa induced dyskinesia (PD-LID) symptom is to a sufficient level to attain a clinical effect.

(Item 12C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, which is a transdermally administered formulation.

(Item 13C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, which is an adhesive formulation.

(Item 14C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, wherein the transdermally administered formulation is a tape/patch.

(Item 15C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one

of the preceding items, wherein a drug dosage of the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is 0.1 to 100 mg per day as a free form of tandospirone.

(Item 16C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, wherein an amount of drug penetration for the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is 0.1 to 20 mg per day as a free form of tandospirone.

(Item 17C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is a transdermally administered formulation, and a total applied area per dose is 1 to 100 cm².

(Item 18C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered so that a human blood (plasma) tandospirone concentration is 0.05 to 20 ng/mL for 12 hours or longer per day.

(Item 19C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered so that a human blood (plasma) tandospirone concentration is 0.05 to 20 ng/mL for 8 to 16 hours after administration of the tandospirone or a pharmaceutically acceptable salt or prodrug thereof.

(Item 20C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is an adjunct of levodopa.

(Item 21C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, which is used with levodopa as the fixed-dose combination or concomitantly as separate formulations.

(Item 22C)

A combination of tandospirone or a pharmaceutically acceptable salt or prodrug thereof and (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa for treating or preventing Parkinson's disease without accompanying or by minimizing PD-L1D, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 23C)

Tandospirone or a pharmaceutically acceptable salt or prodrug thereof for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered in combination with (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 24C)

A combination of (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID, wherein the combination of (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa is administered in combination with tandospirone or a pharmaceutically acceptable salt or prodrug thereof, and wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 25C)

Tandospirone or a pharmaceutically acceptable salt or prodrug thereof for improving the exacerbation in quality of response to levodopa therapy of a Parkinson's disease patient with dyskinesia, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.

(Item 26C)

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of any one of the preceding items, which is a free form.

[0011] In a specific embodiment, the present invention is provided as an adhesive formulation (also referred to as a transdermal patch/tape agent). When the tape agent of the invention is applied, dyskinesia symptoms associated with levodopa therapy for Parkinson's disease can be more preferably prevented or improved. Therapy of Parkinson's disease wherein a single dose and/or a daily dose of levodopa is increased, relative to prior to therapy using the tape agent of the invention, without exacerbation of dyskinesia, can be administered in an actual clinical setting when the tape agent of the invention is applied to more preferably prevent or improve dyskinesia symptoms associated with levodopa therapy for Parkinson's disease.

Current therapy attempts to treat Parkinson's disease patients with small and frequent doses of levodopa to prevent the manifestation of dyskinesia (Parkinsonbyo Shinryo Gaidorain 2018 bajon [Parkinson's Disease Diagnosis and Treatment Guidelines 2018 version] (Third edition, Q&A for Parkinson's disease diagnosis, Chapter III, Therapy for motor symptoms)).

The manifestation of dyskinesia can be suppressed and the levodopa containing for-

mulation can be adjusted to an optimal dose by administering a parenterally administered formulation of tandospirone provided by the invention. In other words, a more preferred therapy of Parkinson's disease symptoms is enabled without exacerbating dyskinesia symptoms, even if a single dose of levodopa is increased to reduce the number of doses or the daily dosage of levodopa is increased for Parkinson's disease patients with or at a risk of manifestation of dyskinesia.

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof and therapeutic method of the invention enable therapy or prevention to reduce levodopa induced motor complications or levodopa induced dyskinesia involving the normal daily dosage for levodopa therapy specified in Parkinsonbyo Shinryo Gaidorain 2018 bajon [Parkinson's Disease Diagnosis and Treatment Guidelines 2018 version] published by the Japanese Society of Neurology or a corresponding guideline in the US or Europe.

Further, a more preferred effect of improving levodopa induced dyskinesia (PD-LID) or the like can be provided relative to oral administration by administering a parenterally administered formulation of tandospirone provided by the invention.

The inventors have found for the first time that oral administration of tandospirone with expectation of an effect of improving dyskinesia instead leads to temporary exacerbation of dyskinesia. In other words, the inventors have found that oral administration of tandospirone is not preferable as a therapeutic drug for the improvement of dyskinesia because the oral administration involves a "rebound symptom" of dyskinesia. As used herein, "rebound symptom" is the symptom described in [0036]. Since oral administration of tandospirone results in a "rebound symptom", it is not preferable to increase the dosage of a levodopa containing formulation.

The inventors have found that the tandospirone parenteral composition of the invention can improve dyskinesia without a "rebound symptom". A dyskinesia score can be measured as an "AIMs score" (AIMs is an abbreviation for "abnormal involuntary movements") by the method described in [0038].

Therefore, the present invention can be practiced as the following specific embodiments.

- (1) A method of preventing or treating Parkinson's disease, a method of improving dyskinesia, or a method of preventing or treating Parkinson's disease with improved dyskinesia, comprising:
 - (A) parenterally administering tandospirone; and
 - (B) administering an increased dosage of levodopa compared to a conventional dosage.
- (2) A method of preventing or treating Parkinson's disease, a method of improving dyskinesia, or a method of preventing or treating Parkinson's disease with improved dyskinesia, comprising:

- (A) parenterally administering tandospirone; and
- (B) increasing the dosage of levodopa to more than a conventional single dosage to adjust the number of daily dosages.
- (3) A method of preventing or treating Parkinson's disease, a method of improving dyskinesia, or a method of preventing or treating Parkinson's disease with improved dyskinesia in a patient with or at a risk of manifestation of dyskinesia, comprising:
 - (A) parenterally administering tandospirone; and
 - (B) administering levodopa with a maintained or increased dosage.
- (4) A method of preventing or treating Parkinson's disease, a method of improving dyskinesia, or a method of preventing or treating Parkinson's disease with improved dyskinesia in a patient with or at a risk of manifestation of dyskinesia, comprising:
 - (A) adding parenteral administration of tandospirone to conventional levodopa therapy; and
 - (B) increasing a levodopa dosage to the extent that dyskinesia is not exacerbated and concomitantly using parenteral administration of tandospirone.
- (5) A method of preventing or treating Parkinson's disease, a method of improving dyskinesia, or a method of preventing or treating Parkinson's disease with improved dyskinesia comprising:
 - (A) maintaining a plasma concentration of tandospirone to 0.05 to 20 ng/mL; and
 - (B) administering levodopa.
- (6) A method of preventing or treating Parkinson's disease, a method of improving dyskinesia, or a method of preventing or treating Parkinson's disease with improved dyskinesia in a patient with or at a risk of manifestation of dyskinesia, comprising:
 - (A) maintaining a plasma concentration of tandospirone to 0.05 to 20 ng/mL; and
 - (B) administering levodopa.

The basis of the invention is the following.

*Since levodopa has a short half-life and the effect is not sustained, levodopa is generally administered multiple times per day. Meanwhile, the blood concentration of tandospirone is maintained for 24 hours when the tandospirone of the invention is administered as a tape agent, i.e., applied one sheet per day. For this reason, for transdermally administered formulations, levodopa is administered while being exposed to tandospirone no matter at what time levodopa is administered. On the other hand, if a Sediol tablet and levodopa are administered (orally administered) at the same timing three times a day, levodopa would be administered while the blood concentration of tandospirone is reduced. In other words, the feature is in being different from an oral agent. Further, it is preferable that the blood concentration of tandospirone is maintained upon administration of levodopa.

[0012] In a specific embodiment, the present invention can be used in various applications

(indications). For example, indications such as improvement of dyskinesia (anti-dyskinesia drug) <PD-LID improving drug>, treating dyskinesia (involuntary movements) in Parkinson's disease patients treated with levodopa therapy, with or without other medicines that increase the effects of dopamine in the brain, a caution for use or a label (package insert) can be appended.

[0013] The present invention is intended so that one or more of the aforementioned features can be provided not only as the explicitly disclosed combinations, but also as other combinations. Additional embodiments and advantages of the present invention are recognized by those skilled in the art by reading and understanding the following detailed description, as needed.

As used herein, motor complications and dyskinesia refer to symptoms associated with levodopa therapy for Parkinson's disease, and exclude symptoms originating from other diseases and symptoms associated with therapy using a compound other than levodopa, unless specifically noted otherwise.

Advantageous Effects of Invention

[0014] The pharmaceutical composition of the invention has expectation as a therapeutic drug, improving drug, progression suppressing drug, or prophylactic drug for levodopa induced motor complications in Parkinson's disease (e.g., levodopa induced dyskinesia (PD-LID), or the like). Specifically, the pharmaceutical composition of the invention has expectation as a therapeutic drug, improving drug, progression suppressing drug, or prophylactic drug for PD-LID without a rebound symptom.

Brief Description of Drawings

[0015] [fig.1] Figure 1 is a diagram showing changes in plasma concentration when a tandospirone tape agent was applied to a normal rat. Specifically, changes in plasma tandospirone concentrations obtained by applying a tandospirone tape agent to a normal rat (9 cm²: 31 ± 2 cm²/kg) are shown in terms of mean value ± standard deviation. The x axis indicates the time from application, and the y axis indicates the plasma tandospirone concentration.

[fig.2] Figure 2 is a diagram showing results of evaluating dyskinesia-like symptoms when a tandospirone tape agent was applied to a PD-LID rat model under administration condition 1. Specifically, a tandospirone tape agent was transdermally administered to a PD-LID rat model and levodopa was administered 4 hours later to evaluate dyskinesia-like symptoms. The results are indicated in terms of mean value ± standard error. ** indicates $p < 0.01$, meaning that there is a significant difference compared to a placebo tape agent application group (Wilcoxon rank sum test). In the figure, graph A shows the changes in AIMs score over time after levodopa administration. Graph B shows the total AIMs score in 180 minutes. Graph C shows the total

AIMs score in 100 to 180 minutes.

[fig.3]Figure 3 is a diagram showing the results of evaluating dyskinesia-like symptoms when a tandospirone tape agent was applied to a PD-LID rat model under administration condition 2. Specifically, a tandospirone tape agent was transdermally administered to a PD-LID rat model on which stratum corneum stripping was performed on the tape agent application site, and levodopa was administered 4 hours later to evaluate dyskinesia-like symptoms. The results are indicated in terms of mean value \pm standard error. ** indicates $p < 0.01$, meaning that there is a significant difference compared to a placebo tape agent application group (Wilcoxon rank sum test). In the figure, graph A shows the changes in AIMs score over time after levodopa administration. Graph B shows the total AIMs score in 180 minutes. Graph C shows the total AIMs score in 100 to 180 minutes.

[fig.4]Figure 4 is a diagram showing results of evaluating dyskinesia symptoms upon continuous subcutaneous infusion of tandospirone to a PD-LID rat model. Specifically, tandospirone was subcutaneously and sustainably administered to a PD-LID rat model, and levodopa was administered 4 hours later to evaluate the dyskinesia-like symptoms. The results are indicated in terms of mean value \pm standard error. * indicates $p < 0.05$, meaning that there is a significant difference compared to the solvent administration group (Steel test). In the figure, graph A shows changes in the AIMs score over time after levodopa administration. Graph B shows the total AIMs score in 180 minutes. Graph C shows the total AIMs score in 100 to 180 minutes.

[fig.5]Figure 5 is a diagram showing results of long term evaluation of dyskinesia-like symptoms upon continuous subcutaneous infusion of tandospirone citrate to a PD-LID rat model. Specifically, tandospirone citrate was subcutaneously and sustainably administered to a PD-LID rat model, and dyskinesia-like symptoms were evaluated on the day of starting the administration and on day 13 of administration. The total AIMs score in 180 minutes is indicated in terms of mean value \pm standard error. ** indicates $p < 0.01$, meaning that there is a significant difference compared to a solvent administration group (Wilcoxon rank sum test). In the figure, Graph A shows results on day 0 of implanting a pump. Graph B shows results on day 13 of implanting a pump.

[fig.6]Figure 6 is a diagram showing the effect of continuous subcutaneous infusion of tandospirone citrate to rats treated on one side of the brain with 6-hydroxydopamine on dyskinesia development. Specifically, levodopa was repeatedly administered and tandospirone citrate was subcutaneously and sustainably administered to rats treated on one side of the brain with 6-hydroxydopamine to evaluate the effect on levodopa repeated administration induced dyskinesia-like symptom manifestation. The results are indicated in terms of mean value \pm standard error. * indicates $p < 0.05$, and ** indicates $p < 0.01$, meaning that there is a significant difference compared to the

solvent administration group (Steel test). In the figure, graph A shows the results of levodopa repeated administration over time, and graph B shows results on the day after the completion of tandospirone citrate administration (day 16).

[fig.7]Figure 7 is a diagram showing results of evaluating dyskinesia-like symptoms when tandospirone citrate was orally administered to a PD-LID rat model. Specifically, tandospirone citrate (10 mg/kg, 30 mg/kg as citrate concentration) was orally administered to a PD-LID rat model, and levodopa was administered 5 minutes later to evaluate dyskinesia-like symptoms. The results are indicated in terms of mean value \pm standard error. * indicates $p < 0.05$, meaning that there is a significant difference compared to a solvent administration group (Steel test). In the figure, graph A shows changes in AIMs score over time after levodopa administration. Graph B shows the total AIMs score in 180 minutes. Graph C shows the total AIMs score in 100 to 180 minutes.

[fig.8]Figure 8 shows results of evaluating dyskinesia-like symptoms when tandospirone citrate was orally administered to a PD-LID rat model. Specifically, tandospirone citrate (30 mg/kg, 100 mg/kg as citrate concentration) was orally administered to a PD-LID rat model, and levodopa was administered 5 minutes later to evaluate dyskinesia-like symptoms. The results are indicated in terms of mean value \pm standard error. In the figure, graph A shows changes in AIMs score over time after levodopa administration. Graph B shows the total AIMs score in 180 minutes. Graph C shows the total AIMs score in 100 to 180 minutes.

[fig.9]Figure 9 is a diagram showing X-ray powder diffraction patterns of tandospirone free form, tandospirone citrate (hydrate), and tandospirone citrate (anhydrate).

[fig.10]Figure 10 shows results of evaluating dyskinesia-like symptoms when 1-PP dihydrochloride was subcutaneously administered to PD-LID rat models. Specifically, 1-PP dihydrochloride (10 mg/kg, 30 mg/kg) was subcutaneously administered to PD-LID rat models, and levodopa was administered 5 minutes later to evaluate dyskinesia-like symptoms. Results are indicated in terms of mean value \pm standard error. In the figure, graph A shows changes in AIMs score over time after levodopa administration. Graph B shows the total AIMs score in 180 minutes. Graph C shows the total AIMs score in 100 to 180 minutes.

Description of Embodiments

[0016] The present invention is explained hereinafter while showing the best modes thereof. Throughout the entire specification, a singular expression should be understood as encompassing the concept thereof in the plural form, unless specifically noted otherwise. Thus, singular articles (e.g., "a", "an", "the", and the like in the case of English) should also be understood as encompassing the concept thereof in the plural form, unless


specifically noted otherwise. Further, the terms used herein should be understood as being used in the meaning that is commonly used in the art, unless specifically noted otherwise. Therefore, unless defined otherwise, all terminologies and scientific technical terms that are used herein have the same meaning as the general understanding of those skilled in the art to which the present invention pertains. In case of a contradiction, the present specification (including the definitions) takes precedence.

[0017] (Definitions, etc.)

The definitions and/or the basic technology of the terms that are especially used herein are described hereinafter as appropriate.

[0018] As used herein, "tandospirone" [Chemical name: (1R,2S,3R,4S)-N-[4-{4-(pyrimidin-2-yl)piperadin-1-yl}butyl]-2,3-bicyclo[2.2.1]heptanedicarboximide] has the following structure.

[Chem.1]



A Sediel tablet comprising a citric acid salt of tandospirone as an active ingredient is used for therapy as a serotonergic anxiolytic drug (e.g., Sediel package insert or label, revised in April 2016, 14th edition, Sumitomo Dainippon Pharma Co., Ltd.; see Japanese Laid-Open Publication No. 58-126865). Tandospirone has a beneficial effect on memory in chronic schizophrenia. In particular, it is known that cognitive dysfunction can be improved by administering tandospirone or a pharmaceutically acceptable salt thereof while continuing maintenance therapy using a typical antipsychotic such as haloperidol (see Japanese Laid-Open Publication No. 2002-20291).

[0019] As an active ingredient used in the pharmaceutical composition of the invention, tandospirone (free form) is preferred, but a pharmaceutically acceptable salt of tandospirone or a prodrug of tandospirone can also be used in the same manner. Pharmaceutically acceptable salts and prodrugs of tandospirone include salts of inorganic acid such as hydrochloride, hydrobromide, sulfate, and phosphate and salts of organic acid such as acetate, butyrate, tartrate, citrate, maleate, and fumarate.

[0020] Prodrugs of tandospirone refer to any component, which has a different structure from tandospirone, but can be converted into tandospirone or an active ingredient based thereon by metabolism after administration to exert efficacy.

[0021] Prodrugs of tandospirone refer to compounds that are converted to tandospirone due to a reaction with an enzyme, or the like under physiological conditions in the body, i.e., compounds that are changed into tandospirone as a result of enzymatic oxidation, reduction, hydrolysis, or the like. Prodrugs of tandospirone may also be compounds

that are changed into tandospirone under physiological conditions such as those described in "Iyakuhin no Kaihatsu" [Drug Development], Hirokawa-Shoten Ltd., 1990, Vol. 7, Molecular Design, pp. 163 to 198.

The tandospirone of the invention or a salt or prodrug thereof (hereinafter, also referred to as tandospirones) has excellent serotonin 5-HT_{1A} receptor activation action.

The tandospirone of the invention has low toxicity and is safe.

[0022] A drug with an active ingredient of "tandospirone citrate" is clinically applied as an oral agent as a therapeutic agent for (1) depression or panic in neurosis and (2) physical symptoms, and depression, anxiety, restlessness, or sleep disorder in a psychosomatic disease. Tandospirone is highly selective to serotonin 1A receptors (hereinafter, also referred to as "5-HT_{1A} receptor"), but has low affinity to dopamine 2 receptors (also referred to as "D₂ receptor") in in vitro receptor binding evaluation for various neurotransmitter receptors. For this reason, tandospirone is understood as activating a 5-HT_{1A} receptor and selectively acting on serotonin nerves to exert an effect on neurosis or the like.

[0023] As used herein, "levodopa" (as broadly defined) includes the narrowly defined levodopa (L-3,4-dihydroxyphenylalanine (IUPAC nomenclature is (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid); also called L-dopa) as well as any other drugs attaining the same efficacy as L-3,4-dihydroxyphenylalanine. Examples of such other drugs include, but are not limited to, esters of L-3,4-dihydroxyphenylalanine and salts thereof. Examples of esters of L-3,4-dihydroxyphenylalanine include levodopa ethyl ester (LDEE; ethyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate), levodopa propyl ester; levodopa propyl ester (propyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate), levodopa methyl ester (methyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate), and the like. An ester of L-3,4-dihydroxyphenylalanine can be, for example, a salt including hydrated salt. A salt of levodopa ester can include, but is not limited to, one of octanoate, myristate, succinate, succinate dihydrate, fumarate, fumarate dihydrate, mesylate, tartrate, and hydrochloride. Examples of succinate dehydrate or succinate of ester of L-3,4-dihydroxyphenylalanine include levodopa ethyl ester succinate (LDEE-S) and levodopa ethyl ester succinate dehydrate (LDEE-S-dihydrate or LDEE-S(d))>

[0024] As used herein, "metabolizing enzyme inhibitor of levodopa" refers to any drug having action to inhibit the metabolism of broadly defined levodopa to enhance the action thereof. Examples thereof include dopa decarboxylase inhibitors (DCI) that prevent levodopa from changing into dopamine in the intestine, liver, or blood vessel (examples thereof include carbidopa, α -methyldopa, benserazide (Ro4-4602), α -difluoromethyl-DOPA (DFMD), salts thereof, and the like), catechol-O-methyl

transferase inhibitors (COMT-I) that similarly prevent the decomposition of levodopa before entering the brain (examples thereof include entacapone), monoamine oxidase inhibitors (MAO-I) that prevent the decomposition of dopamine in the brain (examples thereof include selegiline), and the like.

[0025] (Disease/disorder)

[0026] As used herein, "motor complications" refer to any motor symptom that is a problem to be treated found in patients with advanced Parkinson's disease. Examples thereof include dyskinesia (levodopa induced dyskinesia (PD-LID)), which is an involuntary movement associated with levodopa therapy, and the like. Motor complications are understood to be based on excessive action of levodopa, but the mechanism thereof is not necessarily elucidated.

[0027] As used herein, "levodopa induced dyskinesia <involuntary movement> (PD-LID)" refers to involuntary movement of the hand, leg, or body unintentionally weaving, which is induced by levodopa overdose. It is known that dyskinesia is readily manifested if a large amount of levodopa is continuously dosed more than necessary from the initial phase of the disease, and it is very difficult to control once it is manifested, even if the dosage of levodopa is subsequently increased or decreased to various levels. Peak-dose dyskinesia is known as an exemplary symptom of PD-LID. The symptom is manifested on the face, tongue, neck, limbs, body trunk, or the like when the blood levodopa concentration is high.

[0028] Involuntary movement (dyskinesia) refers to a portion of the body moving involuntarily or not stopping, biting of the lips, difficulty in speech, inability to stay still, or difficulty in moving the hand or leg as intended, and is a motor disorder in which involuntary movement is observed in the limbs and/or mouth or face, and/or body axis. Dyskinesia observed in PD patients undergoing therapy with levodopa is known as levodopa induced dyskinesia (LID), which occurs in more than half of PD patients who have had therapy with levodopa for the past 5 to 10 years. The percentage (%) of patients suffering from LID increases with passage of time (for an overview, see, for example, Encarnacion and Hauser, (2008), "Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.", *Eur Neurol*, 60(2), pages 57 to 66).

[0029] Peak-dose dyskinesia is involuntary movement resulting from excessive antiparkinsonian drug. Diphasic dyskinesia is dyskinesia manifested in two phases, i.e., at the start and near the end of the effect of an antiparkinsonian drug.

[0030] As used herein, "pharmaceutically acceptable salt" includes acid and/or base salts formed with inorganic and/or organic acid and base. Examples thereof include acid addition salts and base addition salts. Examples of acid addition salts include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, hydroiodide, nitrate, and

phosphate, and organic acid salts such as citrate, oxalate, phthalate, fumarate, maleate, succinate, malate, acetate, formate, propionate, benzoate, trifluoroacetate, methane-sulfonate, benzenesulfonate, p-toluenesulfonate, and camphorsulfonate. Examples of base addition salts include inorganic base salts such as sodium salt, potassium salt, calcium salt, magnesium salt, barium salt, and aluminum salt, and organic base salts such as trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, tromethamine [tris(hydroxymethyl)methylamine], tert-butylamine, cyclohexylamine, dicyclohexylamine, and N-N-dibenzylethylamine. Furthermore, examples of "pharmaceutically acceptable salt" include amino acid salts of a basic or acidic amino acid such as arginine, lysine, ornithine, aspartic acid, and glutamic acid. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66: 1-19.

- [0031] The tandospirone or a pharmaceutically acceptable salt or prodrug thereof or medicament of the invention can comprise a carrier as needed. As used herein, the term "carrier" refers to a pharmaceutically acceptable substance, composition, or excipient such as a liquid or solid bulking agent, diluent, additive, solvent, base agent, or skin permeation promoting agent, which is associated with or enables the transport or carriage of a target pharmaceutical compound from an organ/tissue of the body or a part thereof to another organ/tissue of the body or a part thereof. "Pharmaceutically acceptable" refers to being compatible with other raw materials in the formulation and being harmless to the subject.
- [0032] Diseases that are treatable in the present invention include any levodopa induced motor complication in Parkinson's disease.
- [0033] In a specific embodiment, a patient who is treatable in the present invention includes Parkinson's disease patients who have or have the potential of manifesting levodopa induced motor complications. Levodopa induced motor complications include levodopa induced dyskinesia.
- [0034] The effect of improvement on levodopa induced dyskinesia in Parkinson's disease in the present invention can be clinically confirmed using a patient diary or a clinical evaluation scale such as Unified Dyskinesia Rating Scale (UDysRS), Clinical Dyskinesia Rating Scale (CDRS), or Abnormal Involuntary Movement Scale (AIMS). The effect of improving dyskinesia can also be confirmed by dyskinesia-like abnormal involuntary movement behavior evaluation in a non-clinical model PD-LID rat model. The improvement, suppression of progression, or prevention of levodopa induced dyskinesia (PD-LID) symptoms, as well as reduction in the period of levodopa induced dyskinesia (PD-LID) manifestation can be measured by using this approach.
- [0035] The present invention can confirm whether a PD-LID symptom is exacerbated by

whether a clinical evaluation scale of dyskinesia such as UDysRS, CDRS, or AIMS has significantly deteriorated relative to before therapy with tandospirone. This can also be confirmed by whether clear exacerbation in a dyskinesia associated symptom is observed from a patient diary. Whether a levodopa induced dyskinesia symptom is accompanied with pain can be confirmed herein with clinical records such as a patient diary.

- [0036] In the present invention, "rebound symptom" of levodopa induced dyskinesia (PD-LID) refers to a phenomenon in which the dyskinesia score is rather exacerbated temporarily by a therapeutic drug for improving dyskinesia. A "rebound symptom" is a phenomenon with more exacerbation in dyskinesia than a case without therapy using a dyskinesia improving drug after the peak period (e.g., 1 hour) of antiparkinsonian action of levodopa during therapy using the dyskinesia improving drug. The symptom is anticipated to manifest in 1 to 6 hours after administration of levodopa.
- [0037] In the present invention, improvement in levodopa induced dyskinesia (PD-LID) without a rebound symptom means that the total score for dyskinesia is improved without exacerbation of dyskinesia, not even temporarily, compared to a case without therapy using a dyskinesia improving drug after levodopa administration. "Without exacerbation of dyskinesia" refers to a condition with dyskinesia (AIMs score of 2 or greater in an AIMs evaluation system of non-clinical PD-LID rat model) and without significant deterioration in the dyskinesia score compared to a case without therapy using a dyskinesia improving drug.
- [0038] A rebound symptom of levodopa induced dyskinesia (PD-LID) can be evaluated with clear dyskinesia-like symptoms (AIMs score of 2 or greater) observed at 120 to 140 minutes after levodopa administration, total AIMs score in 100 to 180 minutes, or the like as an indicator in an AIMs evaluation system of non-clinical PD-LID rat model. Improvement of dyskinesia can be evaluated by a total AIMs score in 180 minutes after levodopa administration. In this AIMs evaluation system of a PD-LID rat model, an AIMs score of 2 or greater is diagnosed as dyskinesia, and a greater number means more severe dyskinesia. An AIMs score of less than 2 is diagnosed as no dyskinesia.
- [0039] The inventors have found that oral administration of tandospirone results in a rebound symptom, so that it is unsuitable for therapy of PD-LID. Meanwhile, the inventors have found that parenteral administration of tandospirone as in the present invention improves levodopa induced dyskinesia (PD-LID) without a rebound symptom. The therapeutic mode is preferably sustained parenteral administration of tandospirone or parenteral administration of a sustained release formulation, and more preferably transdermal administration of tandospirone.
- [0040] As used herein, "adjunct" refers to a drug other than the drug with the primary action. If levodopa is the primary agent, tandospirone and the like is an adjunct in the present

invention.

[0041] The daily dosage of the primary agent levodopa herein is the normal dose for levodopa therapy specified in Parkinsonbyo Shinryo Gaidorain 2018 bajon [Parkinson's Disease Diagnosis and Treatment Guidelines 2018 version] or a corresponding guideline in the US or Europe. In general, the normal daily dose of levodopa is 50 to 1200 mg/day and preferably 100 mg to 600 mg/day in concomitant use or as a combined agent with a peripheral dopa decarboxylase inhibitor (DCI). For example, SINEMET(Registered trademark) (Carbidopa-Levodopa combination tablet) (New Drug Application (NDA) #017555) approved by the FDA is provided as a 1:4 ratio combination tablet (25 mg Carbidopa - 100 mg Levodopa) and 1:10 ratio combination tablet (10 mg Carbidopa - 100 mg Levodopa or 25 mg Carbidopa - 250 mg Levodopa). The daily maintenance dose of SINEMET(Registered trademark) is administered so that Carbidopa would be 70 mg to 100 mg. SINEMET(Registered trademark) is administered at the maximum daily dose of up to 200 mg as Carbidopa.

The tandospirone or a pharmaceutically acceptable salt or prodrug thereof or therapeutic method herein can enable therapy to reduce motor complications associated with administration of a normal dose in levodopa therapy or prevention of motor complications.

[0042] The levodopa dosage can be appropriately adjusted by administering the tandospirone or a pharmaceutically acceptable salt or prodrug thereof of the invention. The dosage can be increased within the range of the single dosage and daily dosage specified in, for example, Parkinsonbyo Shinryo Gaidorain 2018 bajon [Parkinson's Disease Diagnosis and Treatment Guidelines 2018 version] published by the Japanese Society of Neurology or a corresponding guideline in the US or Europe.

[0043] As used herein, "has sustainability" can be determined by those skilled in the art by utilizing known findings in the art while considering the descriptions herein. Specifically, having sustainability can be defined as maintaining a blood drug concentration for an extended period of time and exhibiting an effect of prolonged biological half-life. Examples of compositions having sustainability include various transdermally administered formulations described in [0051], various sustained release injection agents described in [0089], various implanted agents described in [0090], and the like. As used herein, "sustainably administered" refers to sustained administration of an active ingredient in the present invention from outside to inside the body, which can be achieved through transdermal absorption, injection, infusion, or the like while selecting a parenteral route of administration described in [0048].

[0044] As used herein, "clinically significant period" can be determined by those skilled in the art by utilizing known findings in the art while considering the descriptions herein. Specifically, if a significant effect such as prevention, treatment, or alleviation of

motor complications targeted by the present invention is exhibited, the period of time can be defined as a clinically significant period. For "clinically significant improvement" as used herein, if a significant effect such as prevention, treatment, or alleviation of motor complications targeted by the present invention is exhibited, the state can be similarly defined as a clinically significant improvement. The approach to measure such a period or improvement can be appropriately selected by those skilled in the art. For example, any method described herein can be considered. However, the method is not limited thereto. For example, Parkinsonbyo Shinryo Gaidorain 2018 bajon [Parkinson's Disease Diagnosis and Treatment Guidelines 2018 version] published by the Japanese Society of Neurology can also be used. Alternatively, it is reported that the dyskinesia clinical evaluation index (MDS UDysRS Part III) is 2.32 points (Parkinsonism Relat Disord 21: 1349, 2015)). The method can be appropriately determined by considering (1) comparison with a placebo, (2) before and after therapy for each patient, or the like.

[0045] As used herein, "sufficient period to attain a clinical effect" and "sufficient level to attain a clinical effect" can also be determined by those skilled in the art by utilizing known findings in the art while considering the descriptions herein. Specifically, if the period or level that can attain a clinical effect such as prevention, therapy, or alleviation of motor complications targeted by the present invention can be measured, the period or level can be evaluated as a sufficient period to attain a clinical effect. An approach of measuring such a period or level can be appropriately selected by those skilled in the art. For example, any method described herein can be considered. However, the method is not limited thereto. For example, Parkinsonbyo Shinryo Gaidorain 2018 bajon [Parkinson's Disease Diagnosis and Treatment Guidelines 2018 version] published by the Japanese Society of Neurology or a corresponding guideline in the US or Europe can also be used.

[0046] As used herein, "no" "exacerbation of a levodopa induced dyskinesia (PD-LID) symptom in a Parkinson's disease patient" means that an already developed dyskinesia symptom is not exacerbated to a clinically significant degree or is not significantly exacerbated, dyskinesia manifestation period is not prolonged, a symptom is not significantly exacerbated, not even temporarily, as in a rebound symptom of dyskinesia, or a dyskinesia is not newly developed. A dyskinesia symptom can be confirmed, for example, by measurement using UPDRS, UDysRS, CDRS, AIMS, or the like, or a clinical record such as a patient diary.

[0047] As used herein, "exacerbation in quality of response to levodopa therapy of a Parkinson's disease patient" refers to any decrease in responsiveness of a patient to levodopa therapy. Such an exacerbation in the quality of response can be measured from a dyskinesia symptom or the like. "Improvement" of "exacerbation in quality of

response to levodopa therapy of a Parkinson's disease patient" refers to improvement in the degree of dyskinesia symptom in levodopa therapy of each patient. The improvement can be confirmed by measurement using UPDRS, UDysRS, CDRS, AIMS, or the like, or a clinical record such as a patient diary.

[0048] As used herein, "parenteral administration" refers to a dosage form for any route that is not oral administration. Preferably, any mode for administering tandospirone in a mode and level that are effective for levodopa induced motor complications in Parkinson's disease is employed. Examples of means of parenteral administration include administration through transdermal absorption or transmucosal absorption, as well as injection, infusion, and combinations thereof. For example, administration through transdermal absorption or transmucosal absorption exerts an effect by contacting a transdermally administered formulation such as a paste agent, adhesive formulation, or spray to the skin or mucous membrane so that a drug in the formulation migrates into the body through the skin or mucous membrane. Examples of administration via injection or infusion include intravenous, intradermal, subcutaneous, intramuscular, and enteral administration (intestinal infusion), which can also be administered as a bolus and/or sustained infusion. Injection or infusion can use a suspension, liquid agent, emulsion, or implanted agent in an oily or aqueous medium, comprising another formulation substance such as a suspending agent, stabilizer, and/or a dispersant. Enteral administration (intestinal infusion) can provide sustained drug delivery to the proximal small intestine by using a tube or portable infusion pump by percutaneous endoscopic gastrostomy. In a preferred embodiment, parenteral administration can be performed in a form of a sustained administration. Such sustained administration can be accomplished with transdermal patch/tape or the like, injection, infusion, or the like.

[0049] In the present invention, tandospirone or a pharmaceutically acceptable salt or prodrug thereof is preferably administered by a method that can maintain blood drug concentration for a long period of time, and is more preferably administered by a method that can suppress the generation of metabolites. Examples of administration methods include transdermal administration and injection such as subcutaneous, intradermal, and intramuscular administrations. Injection such as subcutaneous, intradermal, and intramuscular administrations is preferably a method of administration that sustains the blood concentration. In particular, transdermal administration is the most preferred because it is an administration method that has a low degree of invasiveness and requires no hospital visits.

[0050] In the present invention, treatment, improvement, suppression of progression, or prevention of motor complications associated with levodopa therapy for Parkinson's disease by parenteral administration including tandospirone or a pharmaceutically ac-

ceptable salt or prodrug thereof is preferred compared to therapy using an active ingredient other than the inventions herein or therapeutic methods and compositions other than the inventions herein from the viewpoint of having no adverse effect on levodopa action time (ON-time), having no adverse effect on parkinsonian symptoms (can be evaluated by UPDRS or the like), having no attenuation in the effect of the invention in repeated administration, capability to reduce the number of doses of levodopa formulations per day by increasing a levodopa formulation to the optimal dose without exacerbating motor complications, and the like.

[0051] "Transdermally administered formulation" refers to a paste agent, adhesive formulation, or spray (aerosol). Specific examples of adhesive formulations include tape agents (transdermal patch), poultice, plaster, and the like, and examples of paste agents include ointment, cream, lotion, liniment, liquid agent, gel, and the like. A transdermally administered formulation is preferably an adhesive formulation and more preferably a tape agent (transdermal patch). Since a "tape agent" is synonymous with a "patch" in the present invention, they are also denoted as "tape/patch" herein.

[0052] A transdermally administered formulation is manufactured by a known method using a pharmaceutically acceptable additive. In one embodiment, a transdermally administered formulation used in the present invention has an adhesive layer provided on a support, and the adhesive layer can be manufactured by including a thermoplastic elastomer or the like. A "thermoplastic elastomer" is an elastomer that softens and exhibits fluidity when heated, and exhibits thermoplasticity of returning to a rubber-like elastic when cooled. Examples thereof include various thermoplastic elastomers such as urethane, acrylic, styrene, and olefin based elastomers.

[0053] For the transdermally administered formulation of the invention, an adhesive layer can comprise nonvolatile hydrocarbon oil. As nonvolatile hydrocarbon oil, a chained saturated hydrocarbon with about 20 to 40 carbons or chained unsaturated hydrocarbon with about 20 to 40 carbons is preferable. Examples thereof include liquid paraffin, squalene, squalane, pristane, and the like. In particular, liquid paraffin is more preferable from the viewpoint of availability. Liquid paraffin is a mixture of colorless, odorless liquid alkanes with 20 or more carbons. In the present invention, liquid paraffin that is in compliance with the specification specified in the Japanese Pharmacopoeia, US Pharmacopoeia, or the like can be preferably used. Nonvolatile hydrocarbon oil with high viscosity is preferred. Use of liquid paraffin with high viscosity is especially preferable from the viewpoint of adhesiveness.

[0054] An adhesive layer can also comprise a tackifier as needed. A tackifier is generally a resin that is commonly used for imparting skin adhesiveness in the art of adhesive formulations. Examples thereof include rosin based resin, polyterpene resin, coumarone-indene resin, petroleum-based resin, terpene-phenol resin, alicyclic saturated hy-

drocarbon resin, and the like. One or more thereof can be selected therefrom and used.

[0055] If transdermal administration is envisioned, this can also be materialized by applying an ointment to the skin.

[0056] A dosage form for parenteral administration (e.g., transdermal administration) of the tandospirone or a pharmaceutically acceptable salt or prodrug thereof disclosed herein, other than a tape/patch, can include powder, spray, ointment, paste, cream, lotion, gel, and liquid solution.

[0057] Ointment, paste, cream, and gel can comprise, in addition to the tandospirone or a pharmaceutically acceptable salt or prodrug thereof disclosed herein, an additive such as animal and plant fat, oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silicic acid, talc, or zinc oxide, or a mixture thereof.

[0058] Powder and spray can comprise, in addition to the pharmaceutical composition disclosed herein, an additive such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, or polyamide powder or a mixture thereof. A spray can further comprise a common high pressure gas such as chlorofluorohydrocarbon or volatile unsubstituted hydrocarbon such as butane or propane.

[0059] In addition to ointment, powder, solution, and the like are also understood to be within the scope of the disclosure herein, as long as it is suitable for parenteral administration.

[0060] A composition suitable for parenteral administration can comprise at least one type of pharmaceutically acceptable aseptic isotonic aqueous or non-aqueous solution, dispersion, suspension, emulsion, implanted agent, or aseptic powder that can be reconstituted into an aseptic injection solution or dispersion immediately before use.

[0061] The composition disclosed herein can be prepared as a suppository for rectal or vaginal administration. The composition can be prepared by mixing one or more compounds according to the disclosure herein with one or more suitable non-stimulatory additives or carriers including cocoa butter, polyethylene glycol, suppository wax, salicylate, or the like. The composition is a solid at room temperature, but is a liquid at body temperature. Thus, the composition melts in the rectum or the vaginal cavity to release the compound in the disclosure herein. A pharmaceutical composition suitable for vaginal administration can include a pessary, tampon, cream, gel, paste, foam, or spray formulation comprising a carrier known to be suitable in prior art.

[0062] As used herein, "drug dosage" is the amount of drug contained in a composition. As used herein, "amount of drug penetration" is the amount of drug intake into the body. If a composition is a transdermally administered formulation, "amount of drug penetration" is the amount of drug that has absorbed into the skin from the transdermally

administered formulation, and is a value calculated by the following equation.

"Amount of residual drug" is the amount of drug remaining in the transdermally administered formulation that has been peeled off after application. This amount can be quantified by the method described in the Examples (Reference Manufacturing Example) ([0098~0101] or the like.

Amount of drug penetration (mg/day) = drug dosage (mg/day) - amount of residual drug (mg/day)

[0063] In the present invention, the drug dosage, amount of drug penetration, amount of residual drug, and blood (plasma) tandospirone concentration are amounts converted in terms of tandospirone free form, unless specifically noted otherwise.

[0064] In the present invention, the dosage or amount of penetration of tandospirone or a salt thereof can be appropriately adjusted depending on the type of compound, symptom/age/body weight/kidney or liver function of the patient, or the like. For example, the daily drug dosage is 0.1 to 100 mg, and preferably 0.2 to 50 mg or the like. Examples of the upper limit thereof include 100 mg, 80 mg, 50 mg, 30 mg, 15 mg, and the like. Examples of lower limit include 0.1 mg, 0.2 mg, 1 mg, 2 mg, 3 mg, and the like. Examples of a preferred range include any combination of these upper limits and lower limits. The daily amount of drug penetration can be 0.1 to 20 mg, preferably 0.2 to 10 mg. Examples of the upper limit thereof include 20 mg, 10 mg, 8 mg, 7 mg, 5 mg, 3 mg, and the like. Examples of the lower limit include 0.1 mg, 0.2 mg, 1 mg, 1.5 mg, and the like. Examples of a preferred range include any combination of these upper limits and lower limits. The dosing frequency can be appropriately adjusted depending on the property of the composition. If the composition is a transdermally administered formulation, the frequency is for example once every 12 hours to once every 7 days. Any frequency therebetween can also be selected, such as once every 2 days, once every 3 days, once every 4 days, or the like. If the composition is an injection formulation, the frequency is, for example, once daily to once every 3 months. Any frequency therebetween can be selected, such as once a week, once every two weeks, once every 4 weeks, once every 3 months, or the like. It is also possible to adjust the dosing time depending on the symptom with a pump-style automatic injector for sustained administration for 24 hours, or for administration only when the patient is awake. The agent can be mixed with a formulation comprising levodopa and sustainably administered.

[0065] In the present invention, tandospirone or a pharmaceutically acceptable salt or prodrug thereof is preferably administered so that the human blood (plasma) tandospirone concentration is 0.05 to 20 ng/mL as the amount converted in terms of a free form in a period during which levodopa is desired to be active. Specifically, the period is 12 hours or longer, preferably 16 hours or longer per day.

- [0066] Examples of the human blood (plasma) tandospirone concentration include 0.05 to 20 ng/mL and the like as an amount converted in terms of free form. Examples of the upper limit thereof include 20 ng/mL, 15 ng/mL, 10 ng/mL, 8 ng/mL, 5 ng/mL, and the like. Examples of the lower limit include 0.05 ng/mL, 0.1 ng/mL, 0.2 ng/mL, 0.5 ng/mL, 1 ng/mL, and the like. Examples of a preferred range include any combination of these upper limits and lower limits. The aforementioned human blood (plasma) tandospirone concentration can be attained with a single administration or as a maintenance concentration by repeated administration.
- [0067] In the present invention, examples of the maximum value (C_{max}) of human blood (plasma) tandospirone concentration include 0.1 to 20 ng/mL and the like as an amount converted in terms of free form. Examples of the upper limit thereof include 20 ng/mL, 15 ng/mL, 10 ng/mL, 8 ng/mL, 5 ng/mL, and the like. Examples of the lower limit include 0.1 ng/mL, 0.2 ng/mL, 0.5 ng/mL, 1 ng/mL, and the like. Examples of a preferred range include any combination of these upper limits and lower limits.
- [0068] In the present invention, examples of the area under the human blood (plasma) tandospirone concentration-time curve (AUC) include 3 to 700 ng·h/mL and the like as an amount converted in terms of free form. Examples of the upper limit thereof include 700 ng·h/mL, 600 ng·h/mL, 400 ng·h/mL, 300 ng·h/mL, 200 ng·h/mL, and the like. Examples of the lower limit include 3 ng·h/mL, 5 ng·h/mL, 10 ng·h/mL, 30 ng·h/mL, and the like. Examples of a preferred range include any combination of these upper limits and lower limits.
- [0069] In the present invention, a composition comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof is a composition characterized by being administered so that the human blood (plasma) tandospirone concentration is 0.05 to 20 ng/mL for 8 to 16 hours after administration of the tandospirone or a pharmaceutically acceptable salt or prodrug thereof.
- [0070] In the present invention, if the composition comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof is a transdermally administered formulation, the formulation application area thereof can generally be adjusted when appropriate, but the total application area per dose is preferably 1 to 100 cm². Examples of the upper limit thereof include 100 cm², 50 cm², 40 cm², 30 cm², 20 cm², and the like. Examples of the lower limit include 1 cm², 2 cm², 4 cm², 9 cm², and the like. Examples of a preferred range include any combination of these upper limits and lower limits, which enables a preferred therapeutic effect to be attained.
- [0071] The tandospirone or a pharmaceutically acceptable salt or prodrug thereof of the invention exceeds the lower limit value of the human blood (plasma) tandospirone concentration within 8 hours, preferably within 6 hours, and more preferably within 4 hours after a single dose, and the human blood (plasma) tandospirone concentration is

maintained in the range between the upper limit and the lower limit for up to 16 hours, preferably up to 18 hours, and more preferably up to 20 hours after the single dose.

[0072] In the present invention, a tandospirone transdermally administered formulation is provided for therapy of Parkinson's disease by concomitant use with a levodopa containing formulation. The tandospirone transdermally administered formulation in the present invention can be expected to have a preferred effect by administration of a levodopa containing formulation after 6 hours, preferably after 8 hours, and more preferably after 12 hours from application of the tandospirone transdermally administered formulation. Further, a stable therapeutic effect is attained without depending on the timing of administering a levodopa containing formulation by repeatedly administering a tandospirone transdermally administered formulation by replacing the formulation every predetermined amount of time.

[0073] A manufacturing method of the transdermally administered formulation of the invention is described hereinafter, but the present invention is not limited thereto.

[0074] The transdermally administered formulation of the invention can be manufactured by a commonly known method. The tape agent of the invention can be manufactured, for example, according to the following Manufacturing Example 1.

[0075] (Manufacturing Example 1)

A common manufacturing method of tape agents (transdermal patch) is described.

The tape agent of the invention can be manufactured by a common method. For example, the tape agent can be manufactured in accordance with the section directed to the manufacture of plaster agents described in "Keihi Tekiyo Seizai Kaihatsu Manyuaru" [Development manual for transdermally applied formulation], supervised by Mitsuo Matsumoto (1985). The tape agent can also be manufactured, for example, by an apparatus, method, or the like described in "Development of Portable Equipment for Manufacturing Transdermal Patches (MEMBRANE), 32(2), 116-119 (2007))".

[0076] Specifically, a common manufacturing method of adhesive tape can be applied for forming an adhesive layer in the manufacture of the tape agent of the invention. A typical example thereof is a solvent coating method, but hot melt coating method, electron beam curing emulsion coating method, or the like can also be used.

[0077] To form an adhesive layer using the solvent coating method, tandospirone, adhesive containing mixture, penetration enhancer, curing agent, and other formulation components are mixed with an organic solvent to prepare an adhesive layer mixture, and the mixture is applied to one side of a support or a release liner and dried, then the organic solvent is removed, and the release liner or support is pasted on before or after drying. The thickness of an adhesive layer of a tape agent is not particularly limited, but is preferably about 10 μm to about 400 μm , more preferably about 20 μm to about 200 μm , still more preferably about 50 μm to about 180 μm , and especially preferably

about 70 μm to about 150 μm .

[0078] (Manufacturing Example 2)

Preparation of other parenterally administered formulations

[0079] An ointment can be manufactured by a commonly known method. An oil and fat ointment can generally be manufactured by heating and melting an oil and fat substrate of hydrocarbons or the like such as oil and fat, wax, or paraffin, adding an active ingredient, mixing to dissolve or disperse the active ingredient, and mixing and kneading until the entire mixture is homogeneous. A water soluble ointment can generally be manufactured by heating and melting a water soluble substrate such as macrogol, adding an active ingredient, and mixing and kneading until the entire mixture is homogeneous.

[0080] An ointment can be manufactured by blending tandospirone with higher alcohols such as cetanol or stearyl alcohol, higher fatty acid such as myristic acid, lauric acid, palmitic acid, stearic acid, or linoleic acid or an ester thereof, wax such as purified lanolin or spermaceti, surfactant such as sorbitan fatty acid ester or sucrose fatty acid ester, and hydrocarbons such as hydrophilic petrolatum, liquid paraffin, or plastibase. The composition of such an ointment formulation is, for example, 0.5 to 10% by weight of tandospirone, 0.1 to 5% of higher alcohol, 1 to 15% by weight of higher fatty acid or ester thereof, 1 to 10% by weight of surfactant, 4 to 10% by weight of wax, and 50 to 80% by weight of hydrocarbon. An ointment can be obtained, for example, by a manufacturing method comprising adding tandospirone and the aforementioned additive components and mixing the ingredients while heating, and maintaining a temperature of 50 to 100°C, and once all the ingredients become a transparent dissolved solution, mixing the ingredients homogeneously with a homogenizer mixer, and then stirring while cooling and allowing the mixture to cool.

[0081] An injection agent or formulation for subcutaneous, intradermal, or intramuscular administration can be manufactured by a commonly known method. Such an injection agent can generally be manufactured by the following method.

(i) An active ingredient is filled directly, or an active ingredient with an addition of an additive is dissolved, suspended, or emulsified into injection water, other aqueous or non-aqueous solution or the like and homogenized, and the solution is filled into an injection container, sealed, and sterilized.

(ii) An active ingredient is filled directly, or an active ingredient with an addition of an additive is dissolved, suspended, or emulsified into injection water, other aqueous or non-aqueous solution, or the like and homogenized, and the solution is aseptically filtered or aseptically prepared and homogenized and then filled into an injection container and sealed.

[0082] The injection agent can also be manufactured as a lyophilized injection agent or

powder injection agent to prevent degradation or inactivation of the active ingredient in a solution.

- [0083] A lyophilized injection agent can generally be manufactured by filling an active ingredient directly, or filling an active ingredient and an additive such as an excipient, which are dissolved into injection water and aseptically filtered, into a container for an injection agent and then lyophilizing, or lyophilizing the ingredient in a specialized container and then directly filling a container therewith.
- [0084] A powder injection agent can generally be manufactured by filling a container for an injection agent with powder obtained by filtration with an aseptic filter and then crystallization or the powder with addition of a sterilized additive.
- [0085] For example, an active ingredient solution is prepared by dissolving tandospirone in water, organic solvent, or mixture of water and organic solvent, together with a surfactant. The resulting solution can be filtered and sterilized with a sterilization filter to prepare an aseptic active ingredient solution. In this regard, the solvent used for the dissolution (water, organic solvent, or mixture of water and organic solvent) is preferably an organic solvent or a mixture of an organic solvent and water, and more preferably a mixture of an organic solvent and water. A sterilization filter is effective for filtration and sterilization, as well as removal of foreign objects originating from raw materials or exogenous foreign objects mixed in during the manufacturing process.
- [0086] Examples of surfactants include polysorbate 80, polysorbate 20, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, poloxamer 188, polyoxyethylene castor oil, benzalkonium chloride, sodium lauryl sulfate, and the like, and two or more thereof can also be used. A surfactant is preferably polysorbate 80. A surfactant is preferably used at about 0.005% (w/v) to about 10% (w/v).
- As the water, purified water, water of the same or higher grade than purified water, or injection water is used. Examples of organic solvent include alcohol solvents (e.g., methanol, ethanol, and the like), aprotic solvents (e.g., acetone, dimethyl sulfoxide, N,N-dimethylacetamide, and the like), and the like, or two or more solvents can be used. The organic solvent is preferably 1-propanol, methanol, ethanol, 2-propanol, acetone, dimethyl sulfoxide, or N,N-dimethylacetamide.
- [0087] The injection agent of the invention can be intramuscularly or subcutaneously injected after attaching an injection needle to a prefilled syringe filled with a formulation. The injection agent can also be administered by aspirating a formulation from a container such as vial filled with the formulation into an injection syringe via an injection needle and then discharging the formulation intramuscularly or subcutaneously. Furthermore, a formulation can be a lyophilized formulation obtained by filling the formulation into a container such as a vial and lyophilizing the formulation, or a powder filled formulation prepared by filling dried powder crystal obtained by

isolating and then drying the active ingredient crystal in the formulation in a container such as a vial. Lyophilized formulations and powder filled formulations can be intramuscularly or subcutaneously injected after aspirating a suspension prepared by suspending the formulation in a container with a suspension solution at the time of use from the container into an injection syringe via an injection needle. The injection agent of the invention can also be intramuscularly or subcutaneously injected after placing a container filled with a formulation on a needleless syringe (syringe capable of administration without an injection needle by utilizing pressure generated by gas, initiating agent, spring, or the like incorporated into an injection device, and having a mechanism for discharging the drug solution filled in the container).

[0088] Example of preparing a sustained injection pump

The injection agent of the invention can be sustainably administered by using a commercially available subcutaneous sustained injection pump. A subcutaneous sustained injection pump is an apparatus for subcutaneously injecting a drug sustainably to a patient via an injection tube, having a drug storage unit and a pump for sustained injection of the drug. Such an apparatus generally has a built-in clock and program that can change the amount of injection per a certain period of time. A drug storage unit is a sealed container filled with a drug solution adjusted to a drug concentration required for the drug efficacy, comprising a drug inlet and outlet for connection to the pump. A pump is a pump that can sustainably inject the drug solution precisely at a minute amount, which is an apparatus that can injection a minute amount of liquid from about 0.1 mL/day to 10 mL/hr. A drug storage unit is filled with and stores an aseptically guaranteed tandospirone solution.

[0089] A sustained injection agent is an injection agent that is applied subcutaneously, intradermally, intramuscularly, or the like in order to release an active ingredient over a long period of time. A sustained injection agent can be manufactured by a commonly known method, generally by dissolving or suspending an active ingredient in plant oil or the like, or by preparing a suspension of microspheres using biodegradable macromolecular compounds.

[0090] An implanted agent is a solid or gel-like injection agent applied using an instrument for implantation under the skin, in the muscle, or the like, or by surgery in order to release an active ingredient over a long period of time. An implanted agent can be manufactured by a commonly known method. An implanted agent can generally be obtained by using a biodegradable macromolecular compound to prepare a pellet, microsphere, or gel-like formulation.

[0091] (Combined drug)

The transdermally administered formulation of the invention can be concomitantly used with an existing therapeutic agent for Parkinson's disease other than levodopa.

Examples of such an existing therapeutic drug for Parkinson's disease include, but are not limited to, dopamine agonists (e.g., bromocriptine, pergolide, talipexole, cabergoline, pramipexole, ropinirole, rotigotine, and the like), monoamine oxidase B (MAOB) inhibitors (e.g., selegiline, rasagiline, and Safinamide), catechol-O-methyltransferase (COMT) inhibitors (e.g., entacapone), amantadine, apomorphine, istradefylline, anticholinergic drugs (e.g., biperiden, trihexyphenidyl, profenamine, and mazaticol), tiapride, droxidopa, carbidopa, zonisamide, and the like.

[0092] The present invention is specifically described in more detail with Reference Examples, Examples, and Test Examples, but the present invention is not limited thereto. The compound names used in the following Reference Examples, Examples, and the like do not necessarily follow the IUPAC nomenclature.

Examples

[0093] The Examples are described hereinafter.

[0094] While the products described in the Examples were used as the specific reagents, the products can be substituted with an equivalent product from other manufacturers (Sigma-Aldrich, Wako Pure Chemical, Nacalai Tesque, R&D Systems, USCN Life Science INC, or the like).


[0095] (Manufacturing Example)

Reference Manufacturing Example 1: Manufacture of tandospirone

Tandospirone

((1R,2S,3R,4S)-N-[4-[4-(pyrimidin-2-yl)piperadin-1-yl]butyl]-2,3-bicyclo[2.2.1]heptanedicarboximide) has the chemical formula set forth below. The manufacturing method thereof is described in Japanese Laid-Open Publication No. 58-126865. The description thereof is incorporated herein by reference.

[Chem.2]



[0096] (Reference Manufacturing Example: Manufacture of tandospirone tape agent)

(Manufacture of tandospirone tape agent)

An acrylic adhesive (MAS683, CosMED Pharmaceutical Co. Ltd., 35.6% by weight solids, 12.5068 g), ethyl acetate (1.5 mL), and polyoxyethylene lauryl ether (0.2530 g) were mixed. An ethyl acetate (5.5 mL) solution of tandospirone (0.32512 g) was prepared and added to the mixture of adhesive and thoroughly stirred. The resulting mixture was spread on a support and dried for one day at room temperature. A release liner was then pasted therewith to manufacture a tandospirone tape agent.

(Manufacture of placebo tape agent)

An acrylic adhesive (MAS683, CosMED Pharmaceutical Co. Ltd., 35.6% by weight solids, 18.6962 g), ethyl acetate (5.5 mL), and polyoxyethylene lauryl ether (0.3520 g) were mixed and thoroughly stirred. The resulting mixture was spread on a support and dried for one day at room temperature. A release liner was then pasted therewith to manufacture a placebo tape agent.

[0097] 50.8 μm of polyethylene terephthalate and/or ethylene vinyl acetate copolymer laminate film (Scotchpak #9732) from 3M Health Care Ltd. was used as the support. Bynasheet 64S-018B from Fujimori Kogyo Co., Ltd. was used as the release liner.

[Table 1]

Table. Drug content in tandospirone tape agent

	Thickness (μm)	Tandospirone content (mg/cm^2)
Formulation 1	99	0.6
Formulation 2	94	0.6
Formulation 3	114	0.7
Formulation 4	105	0.7
Formulation 5	150	1.0

[0098] Measurement of amounts of drug (drug dosage) and residual drug in tape agent

While an example of measurement conditions for the drug dosage and amount of residual drug is described below, another measurement method verified to be able to measure drug dosage or amount of residual drug of tandospirone can be used instead.

<Example of measurement conditions>

Preparation of standard solution

A tandospirone solution (about 4, 20, or 100 $\mu\text{g}/\text{mL}$) is prepared.

Preparation of formulation solution

(1) A tape agent is placed in a container. 10 mL of acetone is added, and ultrasound wave is irradiated thereon for 30 minutes.

(2) 1 mL of methanol is added to 1 mL extract of (1) and mixed.

(3) The solution is filtered with a filter (Millipore: Millex-FH (0.45 μm , PTFE)).

[0099] High performance liquid chromatography (HPLC) condition

Column: YMC-Pack ODS-AM 250 x 4.6 mm (particle size: 5 μm)

Column oven: 40°C

Detector: ultraviolet absorption spectrophotometer (measurement wavelength: 240 nm)

Flow rate: 0.9 mL/min

Amount injected: 10 μL

Mobile phase: 10 mM phosphate buffer (pH 6.8)/acetonitrile mixture (35:65)

[0100] (Evaluation of plasma concentration)

1. Testing method

1.1. Pretreatment operation method

50 μ L of rat plasma sample was fractionated into a polypropylene microtube. 50 μ L of methanol (50 μ L of standard solution for calibration curve sample) and 200 μ L of internal standard solution (Bezafibrate methanol solution: 200 nmol/L, 200 μ L of methanol for blank sample) are added and stirred for about 10 seconds with a mixer. This is centrifuged (4°C, 4500 rpm, 10 min), and then the supernatant is subjected to vacuum filtration using a filter (FastRemover MF 0.2 μ m). 70 μ L of aqueous 10 mmol/L ammonium acetate solution is added to 70 μ L of the resulting filtrate and stirred for about 10 seconds with a mixer to prepare a measurement sample.

The tandospirone concentration is measured by liquid chromatography-mass spectrometry.

[0101] 1.2. Measurement conditions

Column: XSELECT CSH C18, 3.5 μ m, 100 \times 3.0 mm I.D.

Column temperature: 50°C

Mobile phase A: aqueous 10 mmol/L ammonium acetate solution

Mobile phase B: methanol

Flow rate: 0.6 mL/min

Gradient condition:

[Table 2]

Time (min)	0	0.10	5.00	6.00	6.01	9.00
Mobile phase B (%)	15	15	95	95	15	15

Ionization method: electrospray ionization

Detection method: multiple reaction monitoring, positive ion detection mode

Monitor ion: 384.2/122.1 (tandospirone Q1/Q3, m/z), 362.02/138.9 (Bezafibrate Q1/Q3, m/z)

[0102] (Example 1: Evaluation of changes in plasma concentration when tandospirone tape agent is applied to a normal rat)

(Testing method)

Wistar male rats (14-week old, Japan SLC, Inc.) were used. The abdominal regions of the rats were shaved prior to the tape agent evaluation date, and the tape agent of formula 1 was applied to the abdominal regions on the evaluation date (the size was 9 cm²). Blood was collected over time after 2, 4, 6, and 24 hours from administration by the application to analyze the plasma tandospirone concentration. The results are indicated by mean value \pm standard deviation.

[0103] (Results)

Changes in the plasma tandospirone concentration shown in Figure 1 were observed by applying a tandospirone tape agent (9 cm²: 31 ± 2 cm²/kg). It was confirmed that the tape agent smoothed out and sustained the blood concentration of tandospirone.

[0104] (Example 2: Evaluation of the dyskinesia improving effect of tandospirone tape agent)

A rat striatum dopaminergic denervation model using topical administration of 6-hydroxydopamine (hereinafter, also referred to as "6-OHDA") to one side of the brain is known as a typical experimental model for PD-LID (rats treated on one side with 6-OHDA (6-OHDA-lesioned rats)). Dyskinesia-like abnormal involuntary movements (AIMs) manifest in said model with repeated administration of levodopa (Lundblad et al., European Journal of Neuroscience, 2002, 15: 120-132, Winkler et al., Neurobiology of Disease, 2002, 10: 165-186).

[0105] (Testing method)

Wistar male rats (12-week old, Japan SLC, Inc.) were used for the preparation of animal models. Desipramine hydrochloride (25 mg/kg; Wako Pure Chemical) was intraperitoneally administered. After 30 minutes from the administration, the rats were subjected to isoflurane inhalational anesthetic using a general anesthesia apparatus for experimental animals. Under isoflurane anesthesia, the rats were immobilized to a brain stereotaxic instrument. The skin on the head was incised with a surgical scalpel to expose the skull. The coordinates of the bregma used as the origin (AP: 0, ML: 0, DV: 0) was determined, and the coordinates of the right medial forebrain bundle (AP: -4.4 mm, ML: 1.5 mm, DV: 7.8 mm from bregma) were measured. After inserting an injection tube for administration at the measured coordinates, 6-OHDA (9 µg/4 µL; Sigma-Aldrich) inducing dopaminergic denervation was topically injected. After 2 weeks from surgery, apomorphine hydrochloride hemihydrate (0.5 mg/kg; Wako Pure Chemical) was subcutaneously administered, and the rotation movement to the opposite side from the 6-OHDA injected site was observed. Rats with 7 rotations or more per minute were used as rats treated on one side with 6-OHDA.

[0106] To make a PD-LID model, a mixture of levodopa methyl ester hydrochloride (6 mg/kg; Sigma-Aldrich) dissolved in saline and benserazide hydrochloride (15 mg/kg; Sigma-Aldrich) (hereinafter, also referred to as "levodopa containing solution") was intraperitoneally administered once daily to 6-OHDA-lesioned rats. The levodopa containing solution was repeated administered for 3 weeks or longer to observe and evaluate the behavior. The behavior was observed and evaluated in a transparent acrylic cage for 1 minute every 20 minutes after 20 minutes from the intraperitoneal administration of the levodopa containing solution, up until after 3 hours from administration. Observation of behavior was classified into Limb AIMs (involuntary bending

or stretching of front limbs on the opposite side of the disorder, opening/closing of hands, up and down movement of the wrist, chorea-like tremor, dystonia-like stiffening), Axial AIMS (twisting of the upper body/neck to the opposite side of the disorder, losing balance and falling, or maintaining an unstable posture), Orolingual AIMS (trembling of the jaw or violently sticking out the tongue forward), and Locomotive behavior (rotational behavior to the other side of the destruction), and was given a score from 0 to 4 (0: none, 1: less than 30 seconds of manifestation, 2: 30 seconds or more of manifestation, 3: constantly, but stopped with a stimulus such as sound, and 4: constant manifestation, which does not stop with a stimulus such as sound). The sum of the scores for Limb AIMS, Axial AIMS, and Orolingual AIMS in 3 hours was used as the total AIMS score. Individuals with a total AIMS score of less than 10 were excluded from the test as not manifesting a dyskinesia-like symptom. The behavior was observed and evaluated before the drug evaluation date. The rats were assigned to each dosing group by using the 3 hour AIMS score, Locomotive behavior score, and rat body weight as indicators, which were used for evaluation of drugs.

[0107] (Transdermal administration (condition 1))

When evaluating a tape agent, the hair on the abdominal region of rats was shaved before the evaluation date. The tape agent of formulation 2 was applied to the abdominal regions of rats on the evaluation date at 60 cm²/kg (37 mg/kg). After 4 hours from application, a levodopa containing solution was intraperitoneally administered to observe and evaluate the behavior. Individuals with 50% or more of the tape agent coming off during the test were excluded from analysis. After the completion of observation and evaluation of behavior, plasma was collected to analyze the plasma tandospirone concentration.

[0108] (Transdermal administration (condition 2))

When evaluating a tape agent under stratum corneum stripping conditions (tandospirone high exposure conditions), stripping was performed 10 times at the abdominal region of rats using a transpore surgical tape (3M) on the evaluation date, and a tape agent of formulation 3 was then applied at 60 cm²/kg (45 mg/kg). After 4 hours from application, a levodopa containing solution was intraperitoneally administered to observe and evaluate the behavior. Individuals with 50% or more of the tape agent coming off during the test were excluded from analysis. After the completion of observation and evaluation of behavior, plasma was collected to analyze the plasma tandospirone concentration.

[0109] When evaluating dyskinesia-like symptoms, the sum of the Limb AIMS, Axial AIMS, and Orolingual AIMS at each evaluation point was used as the AIMS score. Statistical analysis on test results was performed by Wilcoxon rank sum test using the total AIMS score, which is the sum of AIMS scores for 3 hours, and total AIMS score in 100 to 180

minutes as parameters. ** indicates $p < 0.01$, meaning that there is a significant difference compared to the placebo tape agent application group. The results in the drawings are indicated in terms of mean value \pm standard error.

[0110] (Results)

When tandospirone was transdermally absorbed by applying a tandospirone tape agent (formulation 2: drug dosage of 37 mg/kg) via transdermal administration (condition 1), the total AIMs score was 12.6. Compared to application of a placebo tape agent without tandospirone, the total AIMs score decreased 17.7, so that a significant improvement was observed in dyskinesia-like symptoms (Figures 2-A and B). Further, a clear dyskinesia-like symptom (mean AIMs score of 2 or greater) was not observed for the placebo tape agent application group or the tandospirone tape agent application group at 120 to 140 minutes after levodopa administration. A significant difference was not found between the two groups in the total AIMs score in 100 to 180 minutes (Figure 2-C). The mean value of plasma tandospirone concentrations measured after the completion of observation and evaluation of behavior was 71.8 ng/mL.

[0111] When a high exposure tandospirone was transdermally absorbed by applying a tandospirone tape agent (formulation 3: drug dosage of 45 mg/kg) under stratum corneum stripping conditions via transdermal administration (condition 2), the total AIMs score was 5.8. Compared to application of a placebo tape agent without tandospirone, the total AIMs score decreased 27.1, so that a significant improvement was observed in dyskinesia-like symptoms. A higher effect of improvement was observed under administration condition 2 than under administration condition 1 (Figures 3-A and B). Further, a clear dyskinesia-like symptom (mean AIMs score of 2 or greater) was not observed for the placebo tape agent application group or the tandospirone tape agent application group at 120 to 140 minutes after levodopa administration under stratum corneum stripping conditions. A significant difference was not found between the two groups in the total AIMs score in 100 to 180 minutes (Figure 3-C). The mean value of plasma tandospirone concentrations measured after the completion of observation and evaluation of behavior was 269 ng/mL. The mean value of plasma tandospirone concentration under administration condition 2 was 3 times or higher than that under administration condition 1.

[0112] In view of the above results, tandospirone transdermally administered formulations improved PD-LID symptoms without a rebound symptom.

Further, it was found that the effect on PD-LID and anxiolytic action of tandospirone is exerted at the same dosage in a non-clinical model. The anxiolytic action was evaluated using a rat Vogel conflict test model, and the effect on PD-LID was evaluated in 6-OHDA-lesioned rats. Therefore, the therapeutic effect in the invention

is exerted at the same blood concentration as tandospirone citrate tablets (Sediell tablets) commercially available as anxiolytic drugs.

[0113] (Example 3: Evaluation of dyskinesia improving effect upon continuous subcutaneous infusion of tandospirone)

The efficacy of tandospirone on dyskinesia-like symptoms was evaluated by continuous subcutaneous infusion of tandospirone to PD-LID rat models.

[0114] (Testing method)

As in Example 2, a levodopa containing solution was repeatedly administered to 6-OHDA-lesioned rats for 3 weeks or longer to observe and evaluate the behavior. The behavior was observed and evaluated before the drug evaluation date. The rats were assigned to each dosing group by using the 3 hour AIMs score, Locomotive behavior score, and rat body weight as indicators, which were used for evaluation of drugs. However, individuals with a total AIMs score of less than 10 were excluded from the test as lacking manifestation of a dyskinesia-like symptom. Individuals with a body weight deviating 10% or more from the mean body weight were also excluded from the test to minimize variation in the dosage for each individual.

[0115] Tandospirone (free form) was dissolved in 1 M hydrochloric acid (Nacalai Tesque) and diluted with saline and adjusted to 0.05, 0.25, or 1.25 mg/kg/hour. The prepared solution was used after injection into an ALZET(Registered trademark) Osmotic Pump MODEL 2ML1 (9.68 μ L/hour; DURECT).

[0116] An osmotic pump injected with tandospirone or solvent was implanted under the skin of rats in each group with $n = 6$. After 4 hours, a levodopa containing solution was administered to observe and evaluate the behavior. After the observation and evaluation of behavior, blood was collected from rats in the tandospirone administration group to analyze the plasma tandospirone concentration.

[0117] The results in the drawings are indicated in terms of mean value \pm standard error. The test results were statistically analyzed by comparison with the solvent administration group by Steel test using the total AIMs score in 3 hours and the total AIMs score in 100 to 180 minutes as parameters. * indicates $p < 0.05$, meaning that there is a significant difference.

[0118] (Results)

Continuous subcutaneous infusion of tandospirone dose-dependently improved dyskinesia-like symptoms, and significant improvement was observed at 1.25 mg/kg/hour (Figures 4-A and B). A clear dyskinesia-like symptom (mean AIMs score of 2 or greater) was not found in both the solvent administration group and the tandospirone administration group at 120 to 140 minutes after levodopa administration. Furthermore, the total AIMs score dose-dependently decreased by continuous subcutaneous infusion of tandospirone, and a significant improvement was observed at

1.25 mg/kg/hour in the total AIMs score in 100 to 180 minutes (Figure 4-C). The mean value of plasma tandospirone concentration measured after the completion of the observation and evaluation of behavior was 23.5 ng/mL at 0.05 mg/kg/hour, 119 ng/mL at 0.25 mg/kg/hour, and 541 ng/mL at 1.25 mg/kg/hour.

[0119] In view of the results, continuous subcutaneous infusion of tandospirone dose-dependently improved dyskinesia-like symptoms. The administration did not lead to a rebound symptom at any of the dosages.

[0120] (Example 4: Evaluation of long-term dyskinesia improving effect of continuous subcutaneous infusion of tandospirone)

The sustainability of efficacy of tandospirone on dyskinesia-like symptoms was evaluated by continuous subcutaneous infusion of tandospirone to PD-LID rat model over 2 weeks.

[0121] (Testing method)

A levodopa containing solution was repeatedly administered to 6-OHDA-lesioned rats for 3 weeks or more to observe and evaluate the behavior in the same manner as Example 2. Individuals with a total AIMs score of less than 15 were excluded from the test as not manifesting a dyskinesia-like symptom. The behavior was observed and evaluated before the drug evaluation date. The rats were assigned to each dosing group by using the 3 hour AIMs score, Locomotive behavior score, and rat body weight as indicators, which were used for evaluation of drugs.

[0122] Tandospirone citrate was dissolved into 1 M hydrochloric acid (Nacalai Tesque) and diluted with saline and adjusted to a concentration of 60 mg/mL (concentration of citrate). The prepared solution was used after injection into an ALZET(Registered trademark) Osmotic Pump MODEL 2ML2 (4.53 μ L/hour; DURECT) for releasing a drug solution at a stable rate for 2 weeks.

[0123] An osmotic pump injected with tandospirone citrate or solvent was implanted under the skin of rats in each group with $n = 8$. After 4 hours, a levodopa containing solution was administered to observe and evaluate the behavior (day 0 of implanting the pump). Repeat administration of once daily levodopa containing solution was continued thereafter. The behavior was also observed and evaluated on day 13 of implanting the pump. After each observation and evaluation of behavior, blood was collected from half of the rats ($n = 4$) in the tandospirone administration group to analyze the plasma tandospirone concentration.

[0124] The results in the drawings are indicated in terms of mean value \pm standard error of the total AIMs scores in 3 hours. The test results were statistically analyzed using Wilcoxon rank sum test using the total AIMs score as a parameter. ** indicates $p < 0.01$, meaning that there is a significant difference compared to the solvent administration group.

[0125] (Results)

Significant improvement in dyskinesia-like symptoms was observed compared to the solvent group on day 0 of implanting the pump from continuous subcutaneous infusion of tandospirone citrate (60 mg/mL: mean 0.78 mg/kg/hour as tandospirone citrate) (Figure 5-A). The mean value of the plasma tandospirone concentrations (value converted in terms of free form) measured after the completion of observation and evaluation of behavior was 281 ng/mL. A significant improvement in dyskinesia-like symptoms relative to the solvent group was also observed on day 13 of implanting the pump (Figure 5-B). The mean value of the plasma tandospirone concentrations (value converted in terms of free form) measured after the completion of observation and evaluation of behavior was 143 ng/mL.

[0126] In view of the results, the effect of improving PD-LID symptoms was sustained even after continuous subcutaneous infusion of tandospirone for 13 days.

[0127] (Example 5: Evaluation of the effect of continuous subcutaneous infusion of tandospirone on prevention/suppression of the manifestation of dyskinesia)

Dyskinesia-like abnormal involuntary movement is manifested when levodopa is repeatedly administered to 6-OHDA-lesioned rats. In this regard, the effect of tandospirone on preventing the manifestation of dyskinesia-like symptoms was evaluated by subcutaneous sustained administration of tandospirone from immediately after starting the repeated administration of levodopa.

[0128] (Testing method)

Tandospirone citrate was dissolved into 1 M hydrochloric acid (Nacalai Tesque) and diluted with saline and adjusted to a concentration of 60 mg/mL or 30 mg/mL. The prepared solution was used after injection into an ALZET(Registered trademark) Osmotic Pump MODEL 2ML2 (4.53 μ L/hour; DURECT).

[0129] 6-OHDA-lesioned rats were assigned to each administration group using the number of apomorphine hydrochloride hemihydrate induced rotations and body weight as indicators. An osmotic pump injected with tandospirone citrate or solvent was implanted under the skin of rats on the day after starting repeated administration of a levodopa containing solution with the same composition as Example 2. The behavior was observed and evaluated using the same method as Example 2 on day 3, 5, 9, and 15 after starting the repeated administration of levodopa. The osmotic pump implanted subcutaneously was retrieved after the observation and evaluation of behavior on day 15. The behavior was also observed and evaluated on the following day (day 16 of repeated administration of levodopa).

[0130] The results in the drawings are indicated in terms of mean value \pm standard error of the total AIMs scores in 3 hours. The test results were statistically analyzed by comparison with the solvent administration group using Steel test with the total AIMs

score on day 16 of repeated levodopa administration as the parameter. * indicates $p < 0.05$ and ** indicates $p < 0.01$, meaning that there is a significant difference compared to the solvent administration group.

[0131] (Results)

Continuous subcutaneous infusion of tandospirone citrate (30 mg/mL: mean of 0.41 mg/kg/hour or 60 mg/mL: mean of 0.83 mg/kg/hour) suppressed the increase in total AIMs score associated with repeated administration of levodopa compared to the solvent group (Figure 6-A). The total AIMs score was significantly lower in the group administered with tandospirone citrate compared to the solvent group on the day after the completion of tandospirone citrate administration (Figure 6-B).

In view of the results, continuous subcutaneous infusion of tandospirone prevented onset of PD-LID, and the effect thereof was also sustained to the day after the final dose of tandospirone.

[0132] (Comparative Example 1: Evaluation of oral administration of tandospirone on dyskinesia symptoms)

[0133] (Testing method)

The behavior was observed and evaluated using the same method as Example 2. Tandospirone citrate was suspended in 0.5% methylcellulose solution and orally administered to rats. After 5 minutes, a levodopa containing solution was intraperitoneally administered, and the behavior was observed and evaluated. The results in the drawings are indicated in terms of mean value \pm standard error. The test results were statistically analyzed by comparison with the solvent administration group by Steel test using the total AIMs score in 3 hours and total AIMs score in 100 to 180 minutes as parameters. * indicates $p < 0.05$, meaning that there is a significant difference.

[0134] (Results)

(1) Dyskinesia-like symptom

In the tandospirone citrate (10, 30, or 100 mg/kg as citrate concentration) orally administered groups, a significant change in the total AIMs score was not observed in comparison to the solvent administration group (Figures 7 and 8-A and B). The results suggest that the PD-LID cannot be improved with a tandospirone oral administration formulation.

[0135] At 120 to 140 minutes after levodopa administration, dyskinesia-like symptoms subsided in the solvent administration group, but a clear dyskinesia-like symptom (mean AIMs score of 2 or greater) was observed in the tandospirone citrate oral administration group (30 or 100 mg/kg). Furthermore, when the solvent administration group and tandospirone citrate oral administration group were compared using the total AIMs score in 100 to 180 minutes as the indicator, a significant increase in the total AIMs score was observed in the tandospirone citrate oral administration group (30 or 100

mg/kg) in comparison to the solvent administration group (Figure 7 and 8-C). The result suggests the potential of manifestation of a phenomenon with delayed manifestation and exacerbation of dyskinesia-like symptoms (rebound symptom of dyskinesia) in a formulation for oral administration of tandospirone.

[0136] In view of the above, an improvement in dyskinesia symptoms was not observed in PD-LID rat models in the tandospirone oral administration group (Table 3-(i)). A rebound symptom of dyskinesia was observed in high dosage oral administration group (Table 3-(ii)). In view of the results, oral administration of tandospirone has an insufficient effect of improving dyskinesia, and has a risk of manifestation of a rebound symptom. Therefore, combined therapy with a levodopa formulation is possibly unsuitable.

[0137] [Table 3]

Comparison of dyskinesia-like symptom scores for transdermal and oral administration

	Dosage (mg/kg) Condition	(i) Indicator of degree of improvement in dyskinesia symptom	(ii) Indicator of rebound symptom of dyskinesia
Transdermal administration (Condition 1) (Example 2)	37 (No stripping)	Improvement 17.7**	No effect -0.1
Transdermal administration (Condition 2) (Example 2)	45 (With stripping)	Improvement 27.1**	No effect 0.9
Oral administration (Comparative Example 1)	6.7	No improvement -3.1	Exacerbating trend -3.5
Oral administration (Comparative Example 1)	20	No improvement -6.5 (Figure 7) -8.6 (Figure 8)	Exacerbation -9.1* (Figure 7) -8.5* (Figure 8)
Oral administration (Comparative Example 1)	67	No improvement 2.9	Exacerbation -10.1*

The dosage was described as a numerical value converted in terms of tandospirone free form. The difference in total AIMs score in three hours (#1) is used as an indicator

of a degree of improvement in dyskinesia symptoms, and the difference in total AIMs score in 100 to 180 minutes (#2) is used as an indicator of a rebound symptom of dyskinesia.

(#1) Difference in total AIMs score in 3 hours = (total AIMs score for placebo tape agent or solvent administration group) - (total AIMs score for tandospirone administration group)

(#2) Difference in total AIMs score in 100 to 180 minutes = (total AIMs score in 100 to 180 minutes for placebo tape agent or solvent administration group) - (total AIMs score in 100 to 180 minutes for tandospirone administration group)

**: there is a significant difference ($p < 0.01$), *: there is a significant difference ($p < 0.05$)

[0138] As shown in Table 3, a significant difference in improvement of levodopa induced dyskinesia symptoms was not found with oral administration, but a significant improvement thereof was found with transdermal administration.

Oral administration was also newly found to have a rebound symptom of dyskinesia, so that therapy by oral administration of tandospirone was found to be undesirable. Meanwhile, a rebound symptom of dyskinesia was not observed for transdermal administration.

In view of the above, the therapeutic effect of tandospirone oral administration on levodopa induced dyskinesia symptoms is limited, suggesting that tandospirone transdermal administration is preferable.

[0139] (Comparative Example 2: Evaluation of tandospirone metabolite on dyskinesia symptom)

[0140] The effect of a tandospirone metabolite 1-(2-Pyrimidyl)piperazine (hereinafter, also referred to as "1-PP") on dyskinesia-like symptoms was evaluated.

[0141] (Testing method)

The behavior was observed and evaluated using the same method in Example 2. 1-PP dihydrochloride (Tokyo Chemical Industry) was dissolved in saline and subcutaneously administered to rats. After 5 minutes, a levodopa containing solution was intraperitoneally administered to observe and evaluate the behavior. The results in the drawings are indicated in terms of mean value \pm standard error. The test results were statistically analyzed by comparison with the solvent administration group by Steel test by using the total AIMs score in 3 hours and total AIMs score in 100 to 180 minutes as parameters.

[0142] (Results)

A significant change in the total AIMs score was not found in the 1-PP dihydrochloride (10 or 30 mg/kg) subcutaneous administration group, relative to the solvent administration group (Figures 10-A and B).

[0143] At 120 to 140 minutes after administration of levodopa, a clear dyskinesia-like symptom (mean AIMS score of 2 or greater) was observed in the 1-PP dihydrochloride subcutaneous administration group (10 or 30 mg/kg). When the solvent administration group and the 1-PP dihydrochloride administration group were compared by using the total AIMS score in 100 to 180 minutes as an indicator, an increasing trend in the total AIMS score, albeit not significant, was observed in the 1-PP dihydrochloride administration group relative to the solvent administration group (Figure 10-C). The result suggests the potential of tandospirone metabolite 1-PP inducing a rebound symptom of dyskinesia.

[0144] The result suggests the potential of a rebound symptom of dyskinesia under administration conditions generating the tandospirone metabolite 1-PP. In other words, for tandospirone, a method of administration that can suppress the generation of 1-PP has less effect on rebound symptoms of dyskinesia and is preferable.

[0145] (Example 6: Demonstration in clinical protocol)

The effect of improving PD-LID of the compound of the invention or the combined drug of the invention can be confirmed by a clinical study in accordance with the method described in the following Reference Document 1 (amantadine P3) as clinical study with a suitable design that can evaluate PD-LID (Reference Document 1: JAMA Neurology 2017; 74 (8) 941-949; Reference Document 2: Movement Disorders 2015; 30 (19) 1343-1350).

[0146] More specifically, the effect of improving PD-LID can be confirmed by, for example, administering the tandospirone or a pharmaceutically acceptable salt or prodrug thereof of the invention or a combined drug of the invention for a certain dosing period (examples thereof include, but are not limited to, 8 to 12 weeks) in 20 years old or older patients diagnosed as having Parkinson's disease and comparing the period of dyskinesia manifestation based on a patient diary or score such as UPDRS, UDysRS, CDRS, or AIMS before and after the dosing period or the like.

[0147] The conditions such as the target patient, dosing period, dosage of agent, and evaluation method can be appropriately changed in the above test.

[0148] (Note)

As disclosed above, the present invention is exemplified by the use of its preferred embodiments. However, it is understood that the scope of the present invention should be interpreted solely based on the Claims. The present application claims priority to U.S. patent application No. 16/395,531, the entire contents of which are incorporated herein by reference. It is also understood that any patent, any patent application, and any other references cited herein should be incorporated herein by reference in the same manner as the contents are specifically described herein.

Industrial Applicability

[0149] A parenterally administered tandospirone formulation is useful as a therapeutic drug that improves PD-L1D.

Claims

- [Claim 1] A composition for treating, improving, suppressing the progression, or preventing motor complications associated with levodopa therapy for Parkinson's disease, comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.
- [Claim 2] The composition of claim 1, wherein the parenteral administration is selected from transdermal administration, intradermal administration, subcutaneous administration, intramuscular administration, and a combination thereof.
- [Claim 3] The composition of claim 1 or 2, wherein the parenteral administration has sustainability or is sustainably administered.
- [Claim 4] The composition of any one of claims 1 to 3, wherein the parenteral administration comprises transdermal administration.
- [Claim 5] The composition of any one of claims 1 to 4, wherein the motor complications comprise levodopa induced dyskinesia (PD-LID).
- [Claim 6] A composition for treating, improving, or preventing motor complications associated with levodopa therapy for Parkinson's disease, comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein levodopa induced dyskinesia (PD-LID) is improved without resulting in a rebound symptom, and wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is transdermally administered.
- [Claim 7] The composition of claim 6, wherein levodopa induced dyskinesia (PD-LID) comprises peak-dose dyskinesia, diphasic dyskinesia, and a combination thereof.
- [Claim 8] The composition of claim 6 or 7, wherein the treatment, improvement, suppression of progression, or prevention of motor complications comprises improvement, suppression of progression, or prevention of a levodopa induced dyskinesia (PD-LID) symptom, reduction of a period of levodopa induced dyskinesia (PD-LID) manifestation, or a combination thereof.
- [Claim 9] A composition for accomplishing improvement, suppression of progression, or prevention of a levodopa induced dyskinesia (PD-LID) symptom, reduction of a period of levodopa induced dyskinesia (PD-LID) manifestation, or a combination thereof, comprising tan-


- dospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.
- [Claim 10] The composition of claim 9, wherein the improvement of a levodopa induced dyskinesia (PD-LID) symptom is a clinically significant improvement or greater.
- [Claim 11] The composition of claim 9 or 10, wherein the improvement a levodopa induced dyskinesia (PD-LID) symptom is to a sufficient level to attain a clinical effect.
- [Claim 12] The composition of any one of claim 9 to 11, wherein the composition is a transdermally administered formulation.
- [Claim 13] The composition of any one of claims 9 to 12, wherein the composition is an adhesive formulation.
- [Claim 14] The composition of any one of claims 9 to 13, wherein a transdermally administered formulation is a tape/patch.
- [Claim 15] The composition of any one of claims 9 to 14, wherein a drug dosage of the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is 0.1 to 100 mg per day as a free form of tandospirone.
- [Claim 16] The composition of any one of claims 9 to 15, wherein an amount of drug penetration for the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is 0.1 to 20 mg per day as a free form of tandospirone.
- [Claim 17] The composition of any one of claims 9 to 16, wherein the composition is a transdermally administered formulation, and a total applied area per dose is 1 to 100 cm².
- [Claim 18] The composition of any one of claims 9 to 17, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered so that a human blood (plasma) tandospirone concentration is 0.05 to 20 ng/mL for 12 hours or longer per day.
- [Claim 19] The composition of any one of claims 9 to 18, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered so that a human blood (plasma) tandospirone concentration is 0.05 to 20 ng/mL for 8 to 16 hours after administration of the tandospirone or a pharmaceutically acceptable salt or prodrug thereof.
- [Claim 20] The composition of any one of claims 9 to 19, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is an adjunct of levodopa.
- [Claim 21] The composition of any one of claims 9 to 20, which is used with

levodopa as the fixed-dose combination or concomitantly as separate formulations.

- [Claim 22] A medicament for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID, comprising a combination of tandospirone or a pharmaceutically acceptable salt or prodrug thereof and (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.
- [Claim 23] A medicament for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID, comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is administered in combination with (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.
- [Claim 24] A medicament for treating or preventing Parkinson's disease without accompanying or by minimizing PD-LID, comprising (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa, wherein the (1) levodopa or (2) levodopa and a metabolizing enzyme inhibitor of levodopa is administered in combination with tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.
- [Claim 25] A composition for improving the exacerbation in quality of response to levodopa therapy of a Parkinson's disease patient with dyskinesia, comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.
- [Claim 26] The medicament or composition of any one of claims 1 to 25, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is a free form of tandospirone.


[Fig. 1]

FIG.1




[Fig. 2]

FIG.2




[Fig. 3]

FIG.3




[Fig. 4]

FIG.4




[Fig. 5]

FIG.5




[Fig. 6]

FIG.6




[Fig. 7]

FIG.7



[Fig. 8]


FIG.8



[Fig. 9]


FIG.9

X-ray powder diffraction pattern of tansospirone and salt thereof



[Fig. 10]

FIG.10



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2020/017652

A. CLASSIFICATION OF SUBJECT MATTER**A61P 25/14**(2006.01)i; **A61K 31/506**(2006.01)i

FI: A61K31/506; A61P25/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61P25/14; A61K31/506

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Published examined utility model applications of Japan 1922-1996
 Published unexamined utility model applications of Japan 1971-2020
 Registered utility model specifications of Japan 1996-2020
 Published registered utility model applications of Japan 1994-2020

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

JSTPlus/JMEDPlus/JST7580 (JDreamIII); Cplus/REGISTRY/MEDLINE/EMBASE/BIOSIS/WPIDS (STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2013/156035 A1 (CONCIT PHARMA APS) 24 October 2013 (2013-10-24) Example II, VIII, Figure 2	1-2, 5-11, 15-16, 20-26
Y	Example II, VIII, Figure 2	3-4, 12-14, 17-19
Y	US 2006/0193900 A1 (HISAMITSU PHARMACEUTICAL CO., INC.) 31 August 2006 (2006-08-31) Example 1-5	3-4, 12-14, 17-19
Y	JP 11-228414 A (SUMITOMO PHARMACEUTICALS CO., LTD.) 24 August 1999 (1999-08-24) Claims 1-5, [0026], Example 5-6, Figure 2	3-4, 12-14, 17-19

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

“A” document defining the general state of the art which is not considered to be of particular relevance
 “E” earlier application or patent but published on or after the international filing date
 “L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 “O” document referring to an oral disclosure, use, exhibition or other means
 “P” document published prior to the international filing date but later than the priority date claimed

“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 “X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 “Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 “&” document member of the same patent family

Date of the actual completion of the international search

22 June 2020

Date of mailing of the international search report

07 July 2020

Name and mailing address of the ISA/JP

Japan Patent Office
 3-4-3, Kasumigaseki, Chiyoda-ku, Tokyo
 100-8915, Japan

Authorized officer

UMEDA, Takashi 4C 1785

Telephone No. +81-3-3581-1101 Ext. 3452

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/JP2020/017652

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)			Publication date (day/month/year)
WO	2013/156035	A1	24 October 2013	JP	2015-514727	A	
				US	2015/0104506	A1	
				EP	2838517	A1	
				CN	104411301	A	
				KR	10-2014-0146207	A	
US	2006/0193900	A1	31 August 2006	JP	2006-241179	A	
				EP	1696013	A2	
				AT	437210	T	
JP	11-228414	A	24 August 1999	(Family: none)			